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ABSTRACT 
VIRGINIA SENKOMAGO: The role of human papillomavirus (HPV) viral load in penile 
HPV infection and clearance among young Kenyan men 
(Under the direction of Jennifer S. Smith) 
Persistent infections with human papillomavirus (HPV) types 16 and 18 are 
causes of cervical cancer in women and various penile squamous cell carcinomas 
(SCC) in men. Male circumcision has been found to be protective against penile HPV, 
but the association between circumcision and HPV viral load remains unclear. 
Additionally, the role of HPV viral load in HPV persistence and subsequent development 
of penile SCC is unknown. 
An HPV-ancillary study, nested within a randomized controlled trial (RCT) of 
male circumcision, was conducted in Kisumu, Kenya. Eligible participants were HIV 
seronegative, uncircumcised and aged 18-24. Penile swabs were collected from glans 
and shaft sites every 6 months for 24 months. GP5+/6+ PCR was used to identify HPV 
DNA types. HPV viral load was measured with LightCyler real-time PCR and classified 
as high (>250copies/scrape) or low (250copies/scrape). 
Of 2,299 men with HPV baseline results, 1,159 were randomized to immediate 
circumcision and 1,140 to the control arm and asked to remain uncircumcised until 
study end. The acquisition of high viral load infections in the glans was lower in the 
circumcision than control arm for HPV16 [Hazard Ratio(HR)=0.32(0.20-0.49)] and 
HPV18 [HR=0.34(0.21-0.54)]. For prevalent high viral load infections in the glans at 
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baseline, risk of persistence to 6 months was lower in the circumcision arm [0.20(0.09-
0.34)] than control arm [0.55(0.39-0.68)] for HPV16 and HPV18 [0.17(0.05-0.34) and 
0.50(0.25-0.71), respectively].  
In uncircumcised men, the hazard of HPV16 clearance at 6 months after first 
HPV16 detection was found to be lower for high versus low viral load incident infections 
in the glans [adjusted hazard ratio (aHR) =0.58 (95%confidence interval, 0.36-0.93)]. 
HPV16 and HPV18 clearance in the shaft was comparable for high and low viral load 
infections. 
Male circumcision reduces the acquisition and possibly enhances the clearance 
of high viral load HPV16 or HPV18 infections in the glans, and thus could potentially 
reduce HPV transmission to women. The reduced rate of high versus low viral load 
HPV16 clearance in uncircumcised men could be associated with increased 
development of penile SCC, and may also explain the increase in HPV16 transmission 
in men with high viral load to their female partners.
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CHAPTER 1 
STATEMENT OF SPECIFIC AIMS 
 
Persistent infections with human papillomavirus (HPV) high-risk types 16 and 18 are 
causes of approximately 70% of cervical cancer cases (1). Higher HPV16 or HPV18 viral 
loads in men are believed to be associated with increased HPV transmission female 
partners compared to lower viral loads (2). Male circumcision has been found to be 
protective against HIV and penile HPV incidence, however, the effect of circumcision on 
HPV viral load of incident and prevalent HPV infections remains unclear (3-8).  
In men, persistence of HPV16 and HPV18 infections is believed to cause penile 
squamous cell carcinomas (SCC), particularly basaloid and warty SCC types (9, 10). 
Higher HPV16 or HPV18 viral loads have been associated with decreased HPV 
clearance and increased progress to high grade cervical intraepithelial neoplasia (CIN) 
in women (11-17). However, the association between HPV viral load and HPV 
clearance has not yet been explored in penile HPV infections in men. 
An HPV-ancillary study was nested within a randomized controlled trial (RCT) 
that began in Kisumu, Kenya in February 2002 with the main aim of determining the 
effect of male circumcision on human immunodeficiency virus (HIV) incidence (5, 18). 
Men from the RCT who consented to the collection of penile exfoliated cells every 6 
months and their shipment overseas for HPV DNA and viral load testing were enrolled 
in the ancillary HPV study. The GP5+/6+ PCR assay was used to identify a wide array 
of HPV DNA types (19, 20). HPV viral load testing was conducted using a LightCyler 
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real-time PCR assay; viral load was classified as high or low (>250 versus 250 
copies/scrape) (21). HPV Incidence was defined as the first HPV16 or HPV18-positive 
result in the glans or shaft. HPV clearance was defined as an HPV-negative result in 
participants who were positive for that given HPV type in the same anatomical site 
(glans or shaft) at their last visit. 
 
With the data collected from this study, the following research aims were addressed: 
 
Aim 1: To examine the association between male circumcision and HPV16 or 
HPV18 viral load in Kenyan men aged 18-24. 
 
1.1. To examine the association between circumcision and the incidence of high viral 
load infections for HPV types 16 and 18 in the glans or shaft. 
1.2. To examine the association between circumcision and the prevalence of high 
versus low HPV viral load infections among men with incident HPV 16 or HPV18 
infections in the glans or shaft. 
1.3. To examine the association between circumcision and clearance of prevalent high 
and low viral load infections for HPV types 16 and 18 in the glans or shaft 
Hypotheses: 
Circumcision reduces the incidence of high viral load HPV18 and HPV16 infections. 
Among HPV-positive men, circumcision is associated with a lower prevalence of high 
versus low viral load HPV16 and HPV18 infections. Circumcision increases the 
clearance of prevalent high viral load HPV16 and HPV18 infections. 
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Rationale:  Circumcision and lower HPV viral load in men are believed to be associated 
with reduced HPV transmission to women (2). The effect of circumcision on HPV viral 
load, however, remains unclear. Only one study, an RCT of male circumcision in 
Uganda, has examined the association between male circumcision and penile HPV viral 
load (22).This study did not have longitudinal data on HPV viral load and was therefore 
unable to examine the association between circumcision and the incidence of high viral 
load HPV infections, or the association between circumcision and the clearance of high 
and low viral load prevalent HPV infections. Higher HPV viral loads in men are possibly 
associated with greater HPV transmission to their female partners (2); thus, 
circumcision may reduce the transmission of HPV infections to women by reducing 
incidence and enhancing clearance of high viral load HPV infections in their male 
partners. 
 
Aim 2: To examine the association between viral load at HPV detection and HPV 
clearance in uncircumcised Kenyan men aged 18-24. 
 
2.1. To examine the association between HPV viral load (high versus low) at detection 
of prevalent HPV 16 and 18 infections and HPV clearance in the glans or shaft  
2.2. To examine the association between HPV viral load (high versus low) at detection 
of incident HPV 16 and 18 infections and HPV clearance in the glans or shaft  
 
Hypothesis 
High viral load at HPV detection is associated with a lower rate of HPV clearance for 
prevalent and incident HPV infections compared to low HPV viral load. 
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Rationale: High viral load of high-risk HPV types is suggested to be associated with 
increased HPV persistence in women; however the association between HPV viral load 
and HPV clearance has not been examined among penile HPV infections in men (11-
17). Higher HPV16 or HPV18 viral loads could possibly be associated with lower HPV 
clearance and subsequently increased progression to penile SCC.  
Additionally, higher HPV viral load in men is suggested to be associated with 
increased HPV transmission to their female partners (2). It is believed that lower HPV 
clearance of high versus low viral load HPV infections in men may enhance HPV 
transmission to their female partners; however the association between higher HPV 
viral load and lower HPV clearance in penile HPV infections is yet to be established. 
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CHAPTER 2 
BACKGROUND AND SIGNIFICANCE 
 
 Significance of HPV infections in males 
 
HPV is one of the most common sexually transmitted infections (STIs) worldwide, 
the overall global prevalence of HPV in men ranges from 1% to 84% among low-risk 
and from 2% to 93% among high-risk male populations (23). In Africa, HPV prevalence 
in males has been found to be as high as 58% (23). The overall HPV prevalence at 
baseline in the men who participated in this study was 51%; the type-specific 
prevalences for HPV 16 and HPV 18 were 9.8% and 4.3% respectively (24). HPV 
infection in men is associated with penile, oral and anal cancers as well as HPV 
transmission to females and cervical cancer incidence (25). HPV infection in men has 
also been shown to be associated with an increased risk of HIV acquisition; data from 
men in this study found the risk of HIV acquisition in HPV-positive men to be 1.8 times 
that of HPV-negative men (26) 
 
 Determinants of HPV infection in males 
 Cross-sectional studies examining factors associated with HPV penile cells in 
males have found prevalence to vary by anatomical site; a higher HPV prevalence has 
been detected in the glans/coronal sulcus than in the penile shaft (24). HPV prevalence 
has also been associated with male sexual characteristics such as a greater number of 
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lifetime sexual partners and no condom use. The presence of other sexually transmitted 
infections, particularly N. gonorrhea, C. trachomatis and herpes virus simplex virus type 
2 (HSV-2) has also been associated with a higher prevalence of HPV in males (26). 
Personal characteristics of males including less than a secondary school education and 
less than daily bathing have also been associated with a greater HPV prevalence (24, 
27, 28). Longitudinal studies examining factors associated with acquisition of HPV in 
males have found a greater number of lifetime sexual partners and infection with 
multiple HPV types to be associated with a greater risk of HPV acquisition (29, 30).  
 
 Determinants of HPV clearance in males 
 The average duration of clearance for overall HPV infections in males is reported 
to range from 5.9 - 7.52 months (31). Infection with HIV and multiple HPV types was 
found to be associated with decreased HPV clearance (29, 32). The results on the 
association of age with HPV clearance remain unclear; HPV clearance has to be found 
to increase in older men in one study (30), but was found to have no effect on clearance 
in another study (31). 
 
HPV infection and Development of Penile Carcinomas 
Persistence of HPV16 and HPV18 infections is a risk factor for the development 
of penile squamous cell carcinomas (SCC), particularly basaloid and warty SCC types 
(9, 10). Approximately half (45% - 47.9%) of penile carcinomas have detectable HPV 
DNA and the most common HPV types include HPV16 (30.8%) and HPV18 (6.6%) (33). 
Although invasive penile SCC is rare in comparison to other cancers, incidence in 
developing countries (4.4 and 4.2 per 100,000 in Uganda and Paraguay, respectively) is 
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over 5 times higher than in developed countries and is associated with high morbidity 
and mortality (33, 34). 
 
The role of Male HPV infections in female HPV and cervical cancer  
 
 Even before the association between HPV and cervical cancer was understood, 
male sexual behavior was found to be associated to cervical cancer in female partners. 
Earlier studies found an association between a greater number of male sexual partners 
and cervical cancer even after adjustment for age of first intercourse and number of 
female sexual partners (35). This association generated the hypothesis of an infectious 
cause of cervical cancer.   
 Studies on concordance of HPV infections in heterosexual couples further 
highlight the role of men in transmitting HPV to their female partners. A recent meta-
analysis of HPV concordance studies worldwide including 33 populations found that of 
HPV-positive couples, 63% were infected with one or more of the same HPV types (36). 
Concordance of HPV infection was found to be sex-dependent; 36% of male partners of 
HPV-positive females were found to have the same HPV type, whereas 55% of female 
partners of HPV-positive men were infected with the same HPV type. These findings 
further support higher rates of infection in women when their partners are HPV-positive. 
Concordance of HPV types was found to be significantly higher for types 16, 18 and 11 
that are high-risk types for cervical cancer in women. 
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 Male Circumcision and HPV prevalence, incidence, clearance and transmission 
 
The effect of male circumcision on HPV infections has been investigated by 
several studies. Two global meta-analyses including results from 2 RCTs and several 
longitudinal studies have examined the association between male circumcision and 
HPV prevalence, incidence and clearance (37, 38). Circumcision was found to greatly 
reduce the prevalence of overall penile HPV in both meta-analyses [Odds Ratio (OR) = 
0.57 (0.45 -0.71) and OR= 0.57(0.42-0.77) respectively], particularly in the glans/sulcus 
[OR =0.47 (0.37-0.60)].  
The two meta-analyses found different results on the association between male 
circumcision and acquisition of HPV infections; one meta-analysis found that 
circumcision decreases HPV incidence [Rate Ratio (RR) = 0.75 (0.57-0.99)] and the 
other found no effect of circumcision on HPV incidence [OR = 1.01 (0.66-1.53)] (37, 38). 
However, results from RCTs in Rakai and Kisumu also found that circumcision 
decreases HPV incidence [RR = 0.67 (0.51-0.89) and HR = 0.61 (0.50-0.70) 
respectively] (7, 8). Similarly, both meta-analyses found no effect of male circumcision 
on HPV clearance [RR= 1.33 (0.65, 1.33) and HR =1.57 (0.51 - 4.89), respectively](37, 
38).  However, results from the two RCTs in Rakai and Kisumu found that circumcision 
increases HPV clearance of existing HPV infections [RR= 0.67 (0.51-0.89) and HR 
=1.47 (1.31 -1.64)](7, 8). Due to the heterogeneity of studies included in the meta-
analyses, more studies are needed to understand the association between male 
circumcision and HPV incidence and clearance. Results from two RCTs suggest that 
male circumcision decreases HPV incidence and enhances clearance of existing HPV 
infections. 
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The RCT in Rakai also examined the effect of male circumcision on HPV 
infection in female partners. In HIV-negative men, circumcision was found to decrease 
the prevalence and incidence of HPV in their female partners [PRR =0.72 (0.62 -0.85)] 
(39). However, in HIV-positive men, circumcision was found to have no effect on 
transmission of HPV to female partners (40).  
The Role of HPV Viral Load in the Natural History of HPV infections 
 
Determinants of HPV Viral load in males 
The studies done on HPV viral load in men so far have been cross-sectional and 
focused on the distribution and factors associated with viral load. Flores et al found that 
the penile shaft specimens had the highest viral load values than any another penile 
site, suggesting that the penile shaft is probably the preferred site for viral replication. Xi 
et al found that higher viral load values for types 16 and 18 were associated with current 
smoking status at baseline (41). Other factors such as number of lifetime partners, 
young age, STI infections, and condom use are known risk factors for HPV infection in 
men, but their association with HPV viral load remains unclear (24, 27, 28). 
 
 HPV Viral Load and HPV Transmission from men to women 
The current understanding of the role of HPV viral load in transmission of HPV is 
based on a study of 238 heterosexual couples examining concordance and viral load 
(2). This study longitudinally examined HPV type concordance in females based on the 
viral load of their male partners. Men with detectable viral load levels (>250 
copies/scrape) were more likely to have the same HPV type as their female partners 
than men with viral loads below the detection level (<250 copies/scrape). When 
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stratified by HPV type, the association between viral load in men and concordance was 
observed for HPV 16 but not for HPV 18 and 31. This study showed that men with 
higher viral loads, particularly for HPV type 16, are more likely to transmit infection to 
their partners than men with lower viral loads. 
 
HPV Viral Load and HPV Persistence or Clearance in women 
The current published studies on HPV viral load and persistence or clearance of 
infection have been done in females; to my knowledge, our study would be the first to 
examine this association in men. Several studies in females have found that higher HPV 
viral loads for high risk HPV types are associated with persistence of infection (33-36). 
In these studies, viral load in women was been examined mainly in 2 ways: (binary as 
less than or greater than 100pg/ml) or as a continuous variable. In the studies that 
examined viral load dichotomously, the effect of high baseline viral loads on persistence 
was found to range from OR of 1.3 – 5.7 (13, 42, 43). One study that examined the 
effect of tertiles of viral load on persistence found that the rate of clearance was higher 
for patients with lower viral load tertiles than higher ones [HR =2.8 (1.0-8.1)](12). A 
study examining HPV viral load continuously found that women with ≥ 107 HPV 16 
copies were infected for longer periods of time than women with lower viral load (11). 
More recently, some studies have focused on the dynamics of viral load rather 
than single time point measurements. Marks et al examined viral load in 50 women and 
found that whereas the baseline viral load was not associated with clearance, a >2 log 
decline in viral load over 6 months (2 study visits) was strongly associated with 
clearance [OR =5.5 (1.4 -21.3)] (44). 
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Even though the studies on viral load and persistence or clearance in women 
differ with regards to HPV types examined, viral load tests used, categorization of viral 
load and definitions of persistence or clearance, they suggest that lower viral loads are 
associated with clearance of infections in women, particularly for HPV 16.  
 
HPV Viral load and development of CIN in women 
Several studies that have examined the association between viral load and CIN 
have found greater viral load levels to be associated with greater severity of disease. 
Studies that examined types 16,18, and 31 found a strong association between high 
viral load (33rd percentile) was found to be strongly associated with ≥ CIN 2 (17, 45). A 
dose response-relationship has also been found for this association; the RR for 
association between viral load and CIN3 was found to be 1.9 and 4.5 for 1-10 copies/ 
cell and >1000copies/cell of viral load respectively (14). A few studies have examined 
the association between the dynamics of viral load and CIN, these studies found that 
women who developed CIN2/3 had consistently high or increasing viral load values, 
whereas those who didn’t develop disease had decreasing viral load values over time 
(46, 47). 
 
Biological Plausibility for Proposed Hypotheses 
 
Aim 1:  Male Circumcision reduces acquisition and enhances clearance of high 
viral load HPV infections  
The biological mechanism by which circumcision may reduce HPV viral load is 
unclear, but it is believed that the keratinized skin surface and scar tissue in circumcised 
men reduces the entry and subsequent HPV viral replication in the basal epidermal cells 
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of the penis (39).  Male circumcision is believed to enhance clearance by eliminating the 
moist subpreputial cavity that promotes HPV virus survival and subsequently reduces 
HPV clearance (39). 
 
Aim 2:  High HPV viral load is associated with lower HPV clearance 
The process of HPV infection is described in Figure 2.1 (48). Briefly, HPV viral 
DNA enters basal cells of the dermis and replicates in human cells progressing to the 
epithelium. In the upper layers of the epithelium, replicated virions are shed and can 
initiate new infections. The viral load values obtained are a measurement of the copies 
of a 100ng target DNA region of the HPV viral DNA obtained from samples of exfoliated 
skin cells (21). It is plausible that a greater number of virus-infected cells in high viral 
load infections may lead to a lower rate of HPV clearance by the immune system in 
comparison to low viral HPV viral load (49). 
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Figure 2.1: Natural History of HPV Infections showing HPV viral replication process (48) 
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CHAPTER 3 
METHODS 
 
These analyses use data from two studies: an RCT of the effectiveness of  male 
circumcision in reducing HIV incidence, and an ancillary HPV study conducted in men in 
Kisumu, Kenya from 2002-2007(5, 18). Penile exfoliated cells were collected from the men 
every 6 months for 2 years. Presence of human DNA was evaluated by beta-globin specific 
PCR, followed by agrose gel electrophoresis (19). The GP5+/6+ PCR assay was used to 
identify a wide array of HPV DNA types (19, 20). HPV viral load testing was conducted 
using a LightCyler real-time PCR assay; viral load was classified as high or low (>250 
versus 250 copies/scrape) (21). The 250 copies/scrape cut-point was chosen because 
high HPV viral load (>250 copies/scrape) in men has been associated with increased HPV 
type concordance in female partners (2).  
RCT of Male Circumcision for HIV Prevention: Bailey et al, 2007 
 
The RCT was conducted in Kisumu, Kenya, to determine the effect of male 
circumcision on HIV incidence beginning in February 2002 (5). Inclusion criteria for the 
study included being residents of Kisumu, uncircumcised, aged 18-24, HIV negative, 
sexually active within the past 12 months, blood hemoglobin ≥ 90 g/l, not planning to 
move in the next 2 years and being willing and able to give consent. Exclusion criteria 
included hemophilia or other bleeding disorder, not being completely uncircumcised, 
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high prothrombin time index, absolute indication for circumcision and other medical 
conditions contraindicating surgery.  
 
Screening Visit 
Participants were referred to the RCT by private and public clinics, and peer outreach 
workers recruited participants from local youth organizations. At the screening visits: 
 Potential participants were interviewed to determine age, residence and 
sexual activity history 
 Blood test for hemoglobin (to determine if ≥ 90g/l) were done  
 HIV testing and counseling was provided 
 A physical examination was also done to determine circumcision status.  
All eligible individuals were invited to participate in the study and were given a consent 
form in their preferred language (English, Dholuo or Kiswahili) to take with them and 
read in detail. 
Baseline Visit 
Trained study personnel reviewed the consent form and consenting adults were 
enrolled in the study. At the baseline or randomization visit: 
 An interview was conducted to obtain medical history, socio-demographic and health 
information 
 Blood was drawn for HIV and HSV-2 testing. Serum specimens were tested for HIV 
antibody using 2 rapid tests (Determine, Abbott Diagnostic Division, Hoofddorp, the 
Netherlands; Trinity Biotech, Wicklow, Ireland) and confirmed bydouble ELISA 
(Adaltis Inc, Montreal, Canada; Trinity Biotech, Wicklow, Ireland) at the University of 
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Nairobi. HSV-2 antibodies were tested for in sera using an enzyme-linked 
immunosorbent assay (ELISA) (Kalon). 
 Urine samples were obtained and tested for N. gonorrhea, T. vaginalis and C. 
trachomatis by PCR (Roche Diagnostics) 
 Participants were assigned to the circumcision (intervention) or delayed circumcision 
(control) groups. A total of 2784 participants were enrolled in the RCT, 1391 
participants were assigned to the circumcised group and 1393 were assigned to the 
intervention group. Circumcision was performed on the same day or within a few 
days of randomization; participants were checked for complications 3, 8 and 30 days 
after circumcision. 
 Counseling for HIV and STI prevention was done 
 
Follow-up visits 
Participants were followed every 6 months at approximately 6, 12, 18 and 24 months 
after the baseline visit. At the follow-up visits: 
 An interview was conducted to obtain socio-demographic and health information 
 Counseling for HIV and STI prevention was done 
 STI  testing (as done at baseline) was done and treatment was provided 
 
 Design of HPV Nested Study 
 
Participants enrolling in the parent study of male circumcision and HIV were 
eligible to participate in the HPV study if they were willing and able to give informed 
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consent for the collection of penile exfoliated cell specimens at each visit. Of the 2784 
participants enrolled in the parent RCT, 2299 (83%) consented to participate and were 
enrolled in the ancillary HPV study. 
 
Collection of penile exfoliated cell specimens 
Penile exfoliated cell specimens were collected by a trained physician or clinical 
officer working as part of the main RCT at the randomization visit prior to circumcision 
(i.e. baseline) and every 6 months during follow-up visits. Samples were collected from 
two anatomical sites: the penile shaft and external foreskin (will be referred to as shaft 
specimen); and the glans, coronal sulcus, and the internal tissue of the foreskin (will be 
referred to as glans specimen). Two pre-wetted type 3 Dacron swabs were used to 
collect exfoliated cells from the two separate anatomical sites: one for the shaft 
specimen and the other for the glans specimen. Shaft samples were collected by: (a) 
rubbing the four sides of the external shaft tissue from the proximal to distal penile shaft 
with sufficient pressure; and (b) rubbing the external surface of the foreskin for 
uncircumcised men. Glans samples were collected by: (a) swabbing the tip of the 
urethral opening; completely circling around the urethral orifice 2-3 times; (b) sampling 
the glans by rubbing back and forth from the top to the bottom in a circular motion; and 
(c) sampling the coronal sulcus by rotating the swab three times around its 
circumference. In uncircumcised men, the glans swab included a sample from the inner 
foreskin tissue. 
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Each swab was placed in a sterile 15 ml centrifuge tubes with 2-mL of 0.01 mol/L 
Tris-HCl 7.4 pH buffer with the participant’s ID number, the visit number and type of 
specimen (glans or shaft) (18).  
 
Processing and shipping of collected specimens 
Each sample tube (2 per participant, glans and shaft) was placed in a previously 
labeled centrifuge tubes processed and centrifuged at high speed for 10 minutes in the 
clinic laboratory on the same day as sample was collected. After centrifuging, the 
supernatant was discarded using a Pasteur pipette, and the pellet was resuspended in 
the same volume of 0.01mol/L of Tris-HCl buffer and vortexed. Diluted cell pellets were 
frozen and stored at -75°C. All samples were transported via Fedex in a dry shipper 
(with permission from the Kenyan Ministry of Health) from Kisumu to the Department of 
Pathology at the VU Medical Center in Amsterdam, the Netherlands for HPV DNA 
testing (5, 18). 
 
HPV DNA testing 
DNA was isolated from penile exfoliated cell samples using NucleoSpin 96 
Tissue kit (Macherey-Nagel, Germany) and a Microlab Star robotic system (Hamilton, 
Germany) according to manufacturers’ instructions. Presence of human DNA was 
evaluated by β-globin specific PCR, followed by agrose gel electrophoresis (43). 
Laboratory testing for HPV positivity was performed using a highly sensitive GP5+/6+ 
PCR assay followed by hybridization of PCR products using an enzyme immunoassay 
(EIA) readout with two HPV oligoprobe cocktail probes that detect the following 44 HPV 
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types: HPV6, 11, 16, 18, 26, 30, 31, 32, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 
54, 55, 56,57, 58, 59, 61, 64, 66, 67, 68, 69, 70, 71 (equivalent to CP8061), 72, 73, 81 
(equivalent to CP8304), 82 (IS39 and MM4subtypes), 83 (equivalent to MM7), 84 
(equivalent to MM8), cand85, 86, cand89 (equivalent to CP6108) and JC9710(19). HPV 
genotyping was subsequently performed on GP5+/6+ PCR positive PCR products by 
reverse line blot (RLB) hybridization (19, 20).  For all analyses, HPV16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 58, 59, 66, and 68 were considered high-risk types. HPV types 
detected by EIA but not by RLB genotyping were designated as HPVX, indicating a 
type, sub-type or variant not detectable with probes used for reverse line blot 
hybridization. Low-risk types included all other HPV types. 
 
HPV16/18 DNA viral load testing 
HPV DNA viral load testing was performed on penile exfoliated cell samples that 
contained HPV16 or 18 using a real time PCR assay and a LightCycler instrument 
(Roche, Mannheim, Germany) (21). DNA extraction and purification were conducted 
according manufacturer instructions using 100 μl of the remaining cell suspensions. All 
samples were run in duplicate in the same run and resulting values were averaged. 
Dilutions of cloned pHPV DNA were used to determine the standard curve for the HPV 
target. In order to calculate the number of copies per sample, the amount of HPV DNA 
in one femtogram was multiplied by the dilution factor and divided by the weight of the 
cloned pHPV viral genome.  
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Validity of viral load measures 
The LightCycler real time PCR assay used have previously been  compared to 
another real time PCR method (Taq Man assay) and the GP5+/6+ enzyme 
immunoassay (EIA) to assess validity of measurements obtained (21). The results from 
the validity study showed that the LightCycler method viral load results were strongly 
correlated to those from the TaqMan assay (spearman ρ = 0.87), but less correlated to 
those from the EIA assay (spearman ρ = 0.77). These results showed that viral load 
results obtained with LightCylcer are comparable to those from other real time PCR 
methods; these real time PCR methods are more accurate in measuring viral load than 
EIA methods. 
Results from the duplicate runs done per sample were obtained for baseline 
samples and assessed for agreement. The spearman coefficients for HPV16 and 
HPV18 were found to be 0.97 and 0.96 respectively (unpublished data). These results 
were limited in assessing for variability since they were done in the same run and do not 
account for technical variability, but they show very high agreement in viral load 
measures produced by the LightCycler. 
Statistical Analyses 
 
Aim 1: Effect of male circumcision on incidence and clearance of high and low 
viral load HPV16 and HPV18 infections in Kenyan men 
 
All analyses were performed for each HPV type (HPV16 or HPV18) and 
anatomical site (glans or shaft) separately. Intent-to-treat analyses were performed to 
examine the incidence of high viral load infections in circumcision versus control arms. 
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Men who were randomized to the circumcision arm but were not circumcised (N=23) 
and those randomized to the control arm but were circumcised (N=14) were included in 
the analysis in the group to which they were randomly assigned. Incident infections 
were assumed to occur at the mid-point between the last HPV-negative and first 
subsequent HPV-positive result. Men who tested HPV-negative at each visit were 
censored at their last observed visit. Only the first incident infections for each HPV type 
(HPV16 or HPV18) at each anatomical site (glans or shaft) were included in incidence 
analyses. The Kaplan-Meier method was used to estimate the 24-month cumulative risk 
of HPV16 and HPV18 in the glans or shaft for the circumcision versus control arms. 
Hazard ratios (HRs) comparing the rate of acquisition of high viral load infections in 
circumcision versus control arms were estimated by fitting Cox proportional hazards 
models.  
An additional analysis was conducted among only participants with incident HPV16 
or HPV18 infections to examine associations between circumcision and the prevalence of 
high versus low HPV viral load at time of HPV detection. Potential confounders of the 
association between circumcision and HPV viral load were identified from literature, and 
analyzed using a directed acyclic graph (DAG) (50). Confounders identified included: HIV 
infection, condom use, number of sex partners, bathing frequency, infection with multiple 
HPV types and infection with other STIs (HSV-2, Trichomonas vaginalis, Chlamydia 
trachomatis and Neisseria gonorrhoeae). Log binomial models were used to derive 
prevalence ratios (PRs) comparing the prevalence of high versus low viral load at the time 
of HPV detection for incident infections observed in the circumcision versus control arms. 
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Clearance of prevalent infections detected at enrollment was assumed to occur at 
the mid-point between the last HPV-positive result and the first subsequent HPV-negative 
result. Men were censored at their last observed visit if they tested positive at each 
consecutive visit for the same HPV type at the same anatomical site.  The Kaplan-Meier 
method was used to estimate the cumulative risk of clearance for high and low viral load 
prevalent HPV infections. Risk estimates for clearance of prevalent infections in the 
circumcision versus control arms were compared with a Z test at 6 and 12 months after 
baseline. HPV persistence was defined as the detection of the same HPV type at the same 
anatomical site at 6 and 12 months after baseline in participants who were positive for 
HPV16 or HPV18 at baseline. For all the analyses of incidence and clearance, HR 
estimates accounting for interval censoring were obtained by fitting models assuming 
Weibull distributions for incidence times; results obtained were similar to those from the 
Cox models (data not shown). Sensitivity analyses were performed by restricting analyses 
to samples that tested positive for the presence of human DNA with the beta-globin test.   
 
Aim 2: Association between HPV Viral Load and HPV clearance in uncircumcised 
Kenyan men 
The distribution of participant characteristics by HPV16 or HPV18 viral load (high or 
low) was examined for infections prevalent at baseline. For these analyses, HPV viral load 
results from the glans and shaft samples were combined; high viral load was defined as 
>250 copies/scrape in the glans or shaft, and low viral load was defined as  250 
copies/scrape in both the glans and shaft. Baseline characteristics examined included age, 
education, employment, marital status, bathing frequency, number of sexual partners and 
condom use in the previous 6 months.  
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HPV clearance analyses were performed separately for incident and prevalent 
HPV16 or HPV18 infections. We also examined HPV clearance separately for glans and 
shaft infections since HPV clearance has been shown to vary by anatomical site (8) . 
For each participant, only the first detected HPV16 or HPV18 infection (incident or 
prevalent) at each anatomical site (glans or shaft) was included in clearance analyses. 
Time-to-clearance since HPV detection was calculated starting at the visit date of first 
HPV detection; for prevalent infections the start date was baseline, and for incident 
infections it was the visit date of first HPV detection for each HPV type at each 
anatomical site. Clearance was assumed to occur at the mid-point between the last 
HPV-positive result and the first subsequent HPV-negative result. Men were censored 
at their last observed visit if they remained HPV positive for the same HPV type at the 
same anatomical site for each observed consecutive visit.  
 HPV viral load measurements at first detection of HPV16 or HPV18 prevalent or 
incident infections were used to classify the infections as high (>250 copies/scrape) or 
low ( 250 copies/scrape) viral load infections.  For all the clearance analyses, HPV 
viral load was analyzed as a time-fixed exposure; few HPV16 or HPV18 infections 
(8.4% overall) were observed to change viral load groups during follow-up. The actual 
circumcision status of eligible men at each visit was reviewed to verify that they were 
uncircumcised during HPV detection and clearance; 12 men assigned to the control arm 
were circumcised later in the study, however, in each case circumcision was performed 
after clearance of HPV infections so these men were included in clearance analyses. 
The Kaplan-Meier method was used to estimate the cumulative incidence for 
clearance of high versus low viral load HPV infections at 6 months (6-month risk) and 
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12 months (12-month risk) after HPV detection. Risk ratio estimates were calculated to 
compare 6-month and 12-month clearance risk estimates of high versus low viral load 
infections (51). Potential confounders of the association between HPV viral load and 
HPV clearance were identified from the literature, and analyzed using a DAG (50). 
Confounders identified and included in Cox regression models were: HIV infection, 
condom use, number of sex partners, bathing frequency, infection with multiple HPV 
types, educational attainment, and infection with other STIs (HSV-2, Trichomonas 
vaginalis, Chlamydia trachomatis and Neisseria gonorrhoeae). Adjusted hazard ratios 
(aHRs) comparing the clearance hazard at 6 months for high versus low viral load HPV 
infections were estimated for each HPV type and anatomical site. HRs at 6-months after 
HPV detection could not be obtained in cases where all high viral load or low viral load 
infections cleared by 6 months after HPV detection.  An interaction term between the 
HPV viral load group and time-to-clearance was included in all the Cox regression 
models to account for non-proportional hazards in clearance of high and low viral load 
HPV infections. Sensitivity analyses for clearance of prevalent and incident infections 
were performed by restricting analyses to samples that tested positive for the presence 
of human DNA with the beta-globin test.   
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Figure 3.1: DAG to Assess Potential Confounders for associations between 
Circumcision and HPV Viral load, and HPV Viral load and HPV Clearance. 
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CHAPTER 4 
THE ASSOCIATION BETWEEN MALE CIRCUMCISION AND PENILE HPV VIRAL 
LOAD IN AN RCT IN KISUMU, KENYA 
 
Overview 
 
Persistent infections with human papillomavirus (HPV) types 16 and 18 are causes 
of approximately 70% of cervical cancer cases. Circumcision and lower HPV viral load in 
men are associated with reduced HPV transmission to women. The association between 
circumcision and HPV viral load, however, remains unclear. Penile swabs from glans and 
shaft sites were collected from men in a circumcision trial in Kisumu, Kenya. GP5+/6+ PCR 
was used to identify HPV DNA types. HPV viral load was measured with LightCyler real-
time PCR and classified as high (>250copies/scrape) or low (250copies/scrape). Of 2,299 
men with HPV baseline results, 1,159 were randomized to immediate circumcision and 
1,140 to the control arm and asked to remain uncircumcised until the study ended. The rate 
of acquisition of high viral load infections in the glans was lower in the circumcision than 
control arm for HPV16 [Hazard Ratio(HR)=0.32(95%confidence interval, 0.20-0.49)] and 
HPV18 [HR=0.34(0.21-0.54)]. Among men with incident infections in the glans, prevalence 
of high versus low viral load at HPV detection was lower in the circumcision than control 
arm for HPV16 [Prevalence Ratio(PR)=0.70(0.50-0.99)] and HPV18 [PR=0.59(0.43-0.82)]. 
For prevalent high viral load infections in the glans at baseline, risk of persistence to 6 
months was lower in the circumcision arm [0.20(0.09-0.34)] than control arm [0.55(0.39-
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0.68)] for HPV16 and HPV18 [0.17(0.05-0.34) and 0.50(0.25-0.71), respectively]. Results 
from shaft samples were similar to those from glans samples. Circumcision reduces 
acquisition and enhances clearance of high viral load HPV infections in the glans, and thus 
could potentially reduce HPV transmission to women.  
Introduction 
 
Persistent infections with human papillomavirus (HPV) high-risk types 16 and 18 are 
causes of approximately 70% of cervical cancer cases in women (1). Women with higher 
HPV16 or HPV18 viral loads are more likely to have persistent infections and to progress to 
high grade cervical intraepithelial neoplasia (CIN) than those with lower viral loads (11-17). 
Men with higher HPV16 or HPV18 viral loads have a higher prevalence of flat penile lesions 
and greater HPV type concordance with their female partners than those with lower viral 
loads (2, 52, 53). As a result, higher HPV viral load in men is suggested to be associated 
with increased HPV transmission to their female partners (2).  
Male circumcision has been found to be protective against HIV and penile HPV 
infections (3-8, 37). Three randomized control trials (RCTs) in Kisumu, Rakai and Orange 
Farm, as well as several longitudinal studies have shown that high-risk HPV prevalence is 
lower in circumcised than uncircumcised men (6-8). RCTs in Kisumu and Rakai also found 
that male circumcision reduces the acquisition of high-risk HPV infections and enhances 
clearance of HPV infections over 24 months (7, 8). Prevalence of flat penile lesions after 24 
months was lower in circumcised than uncircumcised men in Kisumu (52).  Among HIV-
negative men in Rakai, lower HPV prevalence was observed in female partners of 
circumcised men than in female partners of uncircumcised men (40). Circumcision and 
lower HPV viral load in men are suggested to be associated with reduced HPV 
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transmission to women, but the association between circumcision and HPV viral load 
remains unclear (2).  
To our knowledge, only the RCT in Rakai, Uganda, has examined the effect of male 
circumcision on penile HPV viral load (22). This study, however, did not have longitudinal 
data on HPV viral load and was therefore unable to examine the association between 
circumcision and incident high versus low viral load HPV infections. The association 
between circumcision and the clearance of high and low viral load HPV infections present 
at baseline (prevalent infections) was also not explored.  
We present the results of an RCT examining the associations between male 
circumcision and the incidence and clearance of high and low viral load infections for HPV 
types16 and 18 in men in Kisumu, Kenya. We have previously shown that male 
circumcision reduces HPV incidence and increases HPV clearance in this RCT (8); here we 
expand on those findings to examine the association between male circumcision and HPV 
viral load. 
Methods 
 
Study population and enrollment  
Uncircumcised men were screened between February 4, 2002 and September 6, 
2005 in Kisumu, Kenya to participate in an RCT of male circumcision (5). The main aim 
of the trial was to determine the effectiveness of male circumcision in reducing HIV 
incidence. Study participants were recruited from sexually transmitted infection (STI) 
clinics, workplaces and community organizations. Study inclusion criteria included being 
uncircumcised, aged 18-24, HIV negative, sexually active within the past 12 months and 
having blood hemoglobin ≥ 90 g/l. Participants who met the study criteria were randomly 
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assigned to either the immediate circumcision arm or to the control arm and asked to 
remain uncircumcised until the end of their 24 months of study participation. This study 
protocol was approved by Institutional Review Boards of the Universities of Illinois at 
Chicago, Manitoba, Nairobi and North Carolina; RTI International and VU University 
Medical Center. 
This analysis includes men from the RCT who consented to the collection of penile 
exfoliated cells and their shipment overseas for HPV DNA and HPV viral load testing. Of 
the 2784 men enrolled in the RCT, 2299 (83%) consented to provide penile swab samples 
and had baseline HPV data; 1159 men were in the circumcision and 1140 in the control 
arm (Figure 4.I). Eligibility for inclusion in incidence and clearance analyses was 
determined for each HPV type (HPV16 or 18) and anatomical site (glans or shaft) 
separately. Participants who were: 1) positive for HPV16 or HPV18 at baseline; 2) had no 
HPV follow-up data; or 3) had missing HPV viral load data were excluded from incidence 
analyses for that specific HPV type and anatomical site. Similar proportions of samples in 
the circumcision and control arms were included in incidence analyses for HPV16 [87% 
versus 89% in glans, 90% versus 93% in shaft, respectively] and HPV18 [91% versus 93% 
in glans, 93% versus 95% in shaft, respectively]. Clearance of prevalent high and low viral 
load infections was examined in participants who were: 1) positive for HPV16 or HPV18 at 
baseline; 2) had follow-up HPV data; and 3) had viral load data for that HPV type and 
anatomical site [HPV16 glans=144(82.2%), HPV16shaft =67(77.9%), HPV18 glans=60 
(75.9%) and HPV18 shaft =24 (80%)].    
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Follow-up and specimen collection 
Participant follow-up visits were scheduled every 6 months for a period of 24 
months. A standardized questionnaire on sociodemographic characteristics and sexual 
behavior was administered by a trained male interviewer at each visit (5). Penile exfoliated 
cell specimens were collected by a trained physician or clinical officer at each study visit 
(18). Samples were collected from two anatomical sites: (i) penile shaft and external 
foreskin (shaft specimen); and (ii) glans, coronal sulcus, and the internal tissue of the 
foreskin (glans specimen). Sampling of the foreskin was conducted only in uncircumcised 
men. Two pre-wetted type 3 Dacron swabs were used to collect penile exfoliated cells from 
the two separate anatomical sites. Each swab was placed in a sterile 15 ml centrifuge 
tubes with 2-mL of 0.01 mol/L Tris-HCl 7.4 pH buffer with the participant’s ID number, the 
visit number, and anatomical site of specimen (glans or shaft). Each sample was 
centrifuged at high speed for 10 minutes in the clinic laboratory on the same day it was 
collected. Excess Tris-HCl buffer was discarded using a Pasteur pipette, and the pellet was 
resuspended in the same volume of 0.01mol/L of Tris-HCl buffer and vortexed. Diluted cell 
pellets were frozen and stored at -75°C. All samples were transported via Fedex in a liquid 
nitrogen dry shipper from Kisumu to the Department of Pathology at VU Medical Center in 
Amsterdam, Netherlands, for HPV DNA testing. 
HPV DNA, HIV and STI Testing 
DNA was isolated from penile exfoliated cell samples using NucleoSpin 96 Tissue kit 
(Macherey-Nagel, Germany) and a Microlab Star robotic system (Hamilton, Germany) 
according to manufacturers’ instructions. Presence of human DNA was evaluated by beta-
globin specific PCR, followed by agrose gel electrophoresis (19). HPV positivity was 
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assessed by GP5+/6+ PCR followed by hybridization of PCR products using an enzyme 
immunoassay readout with two HPV oligoprobe cocktail probes that detect 44 HPV types. 
Subsequent HPV genotyping was performed by reverse line blot (RLB) hybridization of 
PCR products (19, 20).   
HIV testing was performed at each visit using two HIV antibody rapid tests 
(Determine, Abbott Diagnostic Division, Hoofddorp, Netherlands; and Unigold, Trinity 
Biotech, Wicklow, Ireland), and confirmed by double ELISA (Adaltis, Montreal, Canada; 
Trinity Biotech, Wicklow, Ireland) at the University of Nairobi. Urine samples at each visit 
were tested for Trichomonas vaginalis, Neisseria gonorrhoeae and Chlamydia trachomatis 
infections by PCR-based methods (Roche Diagnostics), and serum was tested for Herpes 
simplex virus (HSV)-2 antibodies by a type-specific enzyme-linked immunosorbent assay 
(ELISA) (Kalon). 
HPV Viral Load Testing 
HPV DNA viral load testing was performed on penile exfoliated cell samples that 
contained HPV16 or HPV18 using a real time PCR assay and a LightCycler instrument 
(Roche, Mannheim, Germany) (21). DNA extraction and purification were conducted 
according manufacturer instructions using 100 μl of the remaining cell suspensions. All 
samples were run in duplicate in the same run and resulting values were averaged. 
Dilutions of cloned HPV DNA were used to determine the standard curve for the HPV 
target. To calculate the number of copies per sample, the amount of HPV DNA in one 
femtogram was multiplied by the dilution factor and divided by the weight of the cloned 
pHPV viral genome. HPV viral load was categorized as low (250 copies/scrape) or high 
(>250 copies/scrape). The 250 copies/scrape cut-point for high versus low viral load was 
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chosen because high HPV viral load (>250 copies/scrape) in men has been associated with 
increased HPV type concordance in female partners (2). 
Statistical Analyses 
All analyses were performed for each HPV type (HPV16 or HPV18) and 
anatomical site (glans or shaft) separately. Intent-to-treat analyses were performed to 
examine the incidence of high viral load infections in circumcision versus control arms. 
Men who were randomized to the circumcision arm but were not circumcised (N=23) 
and those randomized to the control arm but were circumcised (N=14) were included in 
the analysis in the group to which they were randomly assigned. Incident infections 
were assumed to occur at the mid-point between the last HPV-negative and first 
subsequent HPV-positive result. Men who tested HPV-negative at each visit were 
censored at their last observed visit. Only the first incident infections for each HPV type 
(HPV16 or HPV18) at each anatomical site (glans or shaft) were included in incidence 
analyses. The Kaplan-Meier method was used to estimate the 24-month cumulative risk 
of HPV16 and HPV18 in the glans or shaft for the circumcision versus control arms. 
Hazard ratios (HRs) comparing the rate of acquisition of high viral load infections in 
circumcision versus control arms were estimated by fitting Cox proportional hazards 
models.  
An additional analysis was conducted among only participants with incident HPV16 
or HPV18 infections to examine associations between circumcision and the prevalence of 
high versus low HPV viral load at time of HPV detection. Potential confounders of the 
association between circumcision and HPV viral load were identified from literature, and 
analyzed using a DAG (Figure 3.1) (50). Confounders identified included: HIV infection, 
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condom use, number of sex partners, bathing frequency, infection with multiple HPV types 
and infection with other STIs (HSV-2, Trichomonas vaginalis, Chlamydia trachomatis and 
Neisseria gonorrhoeae). Log binomial models were used to derive prevalence ratios (PRs) 
comparing the prevalence of high versus low viral load at the time of HPV detection for 
incident infections observed in the circumcision versus control arms. 
Clearance of prevalent infections detected at enrollment was assumed to occur at 
the mid-point between the last HPV-positive result and the first subsequent HPV-negative 
result. Men were censored at their last observed visit if they tested positive at each 
consecutive visit for the same HPV type at the same anatomical site.  The Kaplan-Meier 
method was used to estimate the cumulative risk of clearance for high and low viral load 
prevalent HPV infections. Risk estimates for clearance of prevalent infections in the 
circumcision versus control arms were compared with a Z test at 6 and 12 months after 
baseline. HPV persistence was defined as the detection of the same HPV type at the same 
anatomical site at 6 and 12 months after baseline in participants who were positive for 
HPV16 or HPV18 at baseline. For all the analyses of incidence and clearance, HR 
estimates accounting for interval censoring were obtained by fitting models assuming 
Weibull distributions for incidence times; results obtained were similar to those from the 
Cox models (data not shown). Sensitivity analyses were performed by restricting analyses 
to samples that tested positive for the presence of human DNA with the beta-globin test.   
 
Results 
Characteristics of men enrolled in this RCT have been previously described (5, 8, 
18). Briefly, the median age of eligible study participants was 20 (range 18-24 years). Most 
men were unemployed (65%) and unmarried (93%). At baseline, 44% of participants 
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reported having more than 2 sex partners and 22% reported always using a condom in the 
previous 6 months. The prevalence of other STIs at baseline was low (2% for Trichomonas 
vaginalis, 2% for Neisseria gonorrhoeae and 5% for Chlamydia trachomatis), with the 
exception of HSV-2 (27%). There were no appreciable differences in sociodemographic, 
sexual history, or STI laboratory results at baseline between eligible participants 
randomized to the circumcision and control arms (Table 4.1). 
Incidence of high viral load HPV infections 
The 24-month cumulative risk of high viral load infections in the glans was lower in 
the circumcision than control arm for HPV 16 (2.7% versus 9.5%) and HPV18 (2.2% versus 
6.8%, respectively) (Figure 4.2). In the shaft, the estimated 24-month cumulative risk of 
high viral load infections was comparable in the circumcision and control arms for HPV16 
(2.0% versus 2.6%) and HPV18 (2.0% versus 2.6%, respectively). 
 Of incident HPV infections observed, a total of 151 HPV16 (39.7%) and 135 HPV18 
(69.2%) high viral load infections occurred in either the glans or shaft (Table 4.2). The rate 
of acquisition of high viral load infections in the glans was lower in the circumcision than 
control arm for both HPV16 [HR=0.32 (0.20-0.49)] and HPV18 [HR= 0.34 (0.21- 0.54)] 
(Table I). Similar trends were observed in the shaft for both HPV types [HPV16 HR= 0.79 
(0.42 -1.45) and HPV18 HR= 0.87 (0.48-1.54)]. Sensitivity analysis by restricting to beta-
globin-positive samples yielded similar results (Table 4.2).  
Prevalence of high versus low viral load at detection of incident HPV infections 
Of the incident HPV infections observed in the glans, most infections in control arm 
had high viral loads [53.6% (N=83) for HPV16; 60.5% (N=66) for HPV18] whereas most of 
those in the circumcision arm had low viral loads [62.3% (N=43) for HPV16; 52.2% (N=24) 
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for HPV18]. In the shaft, most HPV16 incident infections had low viral loads [74.3% (N=52) 
in circumcision arm; 72.4 %( N=62) in control arm] whereas most HPV18 incident infections 
had high viral loads [77.8% (N=21) in circumcised arm; 65.0% (N=26) in the control arm]. 
Few men had incident infections in both the glans and shaft (19% for HPV16 and 25% for 
HPV18), and in all these cases the viral load category (high or low viral load) was the same 
in both anatomical sites. 
Among men with incident HPV infections in the glans, the prevalence of high versus 
low viral load at the time of HPV detection was lower in the circumcision than control arm 
for HPV16 [PR=0.70(0.50-0.99)] and HPV18 [PR=0.59(0.43-0.82)]. However, this 
association was not observed in the shaft for HPV 16 [PR = 0.93 (0.55-1.57)] or HPV 18 
[PR = 1.20 (0.88-1.62)] (Table 4.3). PRs obtained after adjustment for HIV infection, 
condom use, number of sex partners, bathing frequency, infection with STIs and multiple 
HPV type infection were similar to the reported unadjusted HRs (results not shown). 
Sensitivity analyses restricted to beta-globin-positive samples showed similar results as the 
main analysis (Table 4.3).  
 
Clearance of high and low viral load infections prevalent at baseline 
For both HPV types, HPV prevalence at baseline was higher in the glans (HPV16 
=6.6%; HPV18 =3.1%) than in the shaft (HPV16 =2.8%; HPV18 =1.1%). Prevalent 
infections in the glans at baseline were more likely to have high HPV viral loads [HPV16= 
54.9% (79); HPV18= 66.7% (N=40) than prevalent infections at baseline in the shaft 
[HPV16= 11.9% (N=8); HPV18= 41.7% (N=10)] (Table 4.4). Similar proportions of men with 
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prevalent HPV16 and HPV18 infections at baseline were assigned to the circumcision and 
control arms (Figure 4. I). 
Nearly all prevalent infections at baseline cleared during follow-up, with the 
exception of 5 (6.6%) HPV16 glans infections in the control arm (4 high viral load infections 
censored at 18 months and 1 low viral load infection censored at 12 months after baseline).  
For both HPV types, most prevalent infections in the glans or shaft cleared within 6 months 
(Figures 4.3 and 4.4). At both 6 and 12 months after baseline, the highest risk of 
persistence for HPV16 and HPV18 infections was among men in the control arm with high 
HPV viral load. The estimated risk of persistence to 6 months for prevalent infections in the 
glans was lower in the circumcision arm [0.20(0.09-0.34)] than control arm [0.55(0.39-0.68)] 
for HPV 16 and HPV18 [0.17(0.05-0.34) and 0.50(0.25-0.71), respectively] (Table 4.4). For 
prevalent HPV16 infections in the glans, the estimated risk of persistence to 6 months for 
high viral load infections in the circumcision arm [0.20 (0.09 – 0.34)] was similar to that of 
low viral load infections in the control arm [0.13 (0.04 -0.26)] (Table 4.4). A similar trend 
was observed for prevalent HPV16 infections in the shaft and prevalent HPV18 infections in 
the glans and shaft.   
HR estimates for clearance of prevalent  infections  were imprecise, but suggest that 
clearance of high viral load infections was greater in the circumcision than control arm for 
HPV16 [HR =1.46 (0.91-2.32) in glans; HR=4.34 (0.67-84.9) in shaft] and HPV18 [HR= 
2.02 (1.02-4.08) in glans; HR = 4.33 (0.78-33.3) in shaft ] (Table 4.4). Results for clearance 
of low viral load infections were also imprecise, but suggest that clearance in the glans was 
greater in the circumcision versus control arm [HR=1.31(0.68 -1.89)for HPV16; HR=1.79 
 37 
(0.70-5.15)for HPV18]. Sensitivity analyses of clearance restricted to prevalent infections 
that were beta-globin-positive found similar results to the main analysis (data not shown). 
 
Discussion 
The two-year cumulative incidence of high viral load HPV16 and HPV18 infections in 
the glans was lower in the circumcision arm than control arm in young men from Kisumu, 
Kenya. Circumcision reduced the rate of acquisition of high viral load HPV16 and HPV18 
infections in the glans over 24 months. Among men with incident HPV16 or HPV 18 
infections, circumcised men were more likely to have low versus high viral load infections in 
the glans as compared to uncircumcised men. We also found that for prevalent high viral 
load infections detected at baseline, the risk of HPV persistence to 6 months was lower in 
the circumcision arm than control arm for both HPV types 16 and 18 in the glans. Similar, 
but less precise results were observed for the estimated effect of circumcision on the 
incidence of high viral load HPV16 and HPV18 infections in the shaft samples. 
To our knowledge, only one study, in Rakai, Uganda, has examined the effect of 
circumcision on HPV viral load in men (22). Also an RCT of male circumcision, the study 
found the combined HPV viral load for HPV types 16, 18, 31, 33, 35 and 52 in the glans 
was lower in the circumcision arm than control arm at 24 months after randomization. Their 
estimated protective effect of circumcision on prevalence of high versus low HPV viral load 
infections in the glans [PR =0.54 (0.21-1.42)] was similar to the PR estimates we obtained 
for HPV16 [0.70 (0.50 -0.99)] and HPV18 [0.59 (0.43 -0.82)] in the glans.  
Our study examined HPV viral load in both the glans and shaft anatomical sites. 
Estimated effects of circumcision in reducing incidence and enhancing clearance of high 
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viral load infections in the shaft were similar, but less precise than estimated effects found 
in the glans. This may be due to fewer HPV infections and a lower proportion of high viral 
load infections detected in the shaft as compared with the glans. Stronger effects of 
circumcision on HPV infection in the glans than more distal anatomical sites to the foreskin 
have been documented in other studies (37). 
The biological mechanism by which circumcision reduces HPV viral load is unclear, 
but it is believed that the keratinized skin surface and scar tissue in circumcised men 
reduces the entry and subsequent HPV viral replication in the basal epidermal cells of the 
penis (39). In uncircumcised men, it has been hypothesized that the moist subpreputial 
cavity promotes HPV virus survival and subsequently reduces HPV clearance (39, 54). 
Male circumcision has been previously shown to reduce the prevalence of flat penile 
lesions; our findings are consistent with the current understanding that circumcision 
reduces the prevalence of flat penile lesions by reducing HPV viral load in men (2, 52, 53). 
Furthermore, the effect of circumcision in reducing HPV viral load may explain why fewer 
HPV infections and lower HPV viral loads are observed in female partners of circumcised 
than uncircumcised men (40, 54). It is possible that circumcision reduces the transmission 
of HPV infections to women by reducing incidence and enhancing clearance of high viral 
load HPV infections in their male partners.  
Main strengths of this study include the extensive longitudinal data on HPV viral load 
and quantitative HPV viral load measurements by real time PCR. Our study is also the first 
to examine type-specific HPV viral load in both the glans and the shaft anatomical sites. 
Our main study limitation is that HPV viral load measurements were not normalized to 
account for number of cells in each swab sample (viral load copies/cell). However, the 
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copies/scrape units have been previously used to show that high HPV viral load (>250 
copies /cell) in men is associated with greater HPV type concordance in their female 
partners (2). We also observed fairly low beta-globin positivity in our samples (61.5% in 
glans and 43.5% in shaft samples). A possible explanation is that penile cells, particularly in 
shaft samples, are more keratinized and anucleated than those in the cervix, and therefore 
may contain less human DNA (24). Lower beta-globin positivity in penile swab samples has 
also been documented in a similar study (7). Due to our low beta-globin positivity, it is 
possible that HPV viral load measurements in this study may be underestimated. However, 
all the incidence and clearance sensitivity analyses restricted to beta-globin positive 
samples found similar results as the main analyses. 
This study adds to the current understanding of HPV viral load in men in general, 
and the natural history of HPV infections in circumcised and uncircumcised men. Like 
previous studies examining HPV viral load in men, the interpretation of our results is limited 
by the inability to distinguish between integrated and episomal DNA (48). Integration is 
followed by a decrease in HPV viral load, but the level of integrated HPV is believed to 
increase with progression of HPV infections (48). Future research distinguishing between 
episomal and integrated DNA is needed to further understand the effect of circumcision on 
HPV viral load. 
Interestingly, we found that the risk of persistence to 6 and 12 months for prevalent 
infections detected at baseline was similar in circumcised men with high HPV viral load and 
uncircumcised men with low HPV viral load, for both HPV types and anatomical sites. This 
suggests that the viral load of prevalent HPV infections may predict HPV clearance 
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independently of circumcision, although this needs to be confirmed in a larger study taking 
into account other factors associated with HPV clearance including treatment of other STIs.  
 In conclusion, this study showed that circumcision reduces acquisition and enhances 
clearance of high viral load HPV infections in the glans in Kenyan men. High HPV viral load 
in men is suggested to be associated with increased HPV transmission to female partners 
(2). Therefore, male circumcision could potentially reduce HPV transmission to women by 
reducing acquisition and enhancing clearance of high HPV viral load infections in men.  
These findings support the effectiveness of male circumcision as an intervention to reduce 
the incidence of and accelerate the clearance of high viral load infections in men, and 
potentially reduce HPV incidence in women.
  
Tables and Figures 
Figure 4.1: Study flowchart of HPV samples included in analyses of the effect of male circumcision on penile HPV 
viral load 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HPV Types HPV 16  HPV 18  
Anatomic Sites Glans Shaft Glans Shaft 
Other Exclusion Criteria : 
 Missing HPV viral load data 
 
19 
 
11 
 
2 
 
1 
HPV (+) at baseline   
Total  samples in 
Clearance Analyses 
68 39 37 12 
HPV (-) at baseline   
Total Samples in Incidence 
Analyses 
1009 1046 1057 1083 
HPV 16  HPV 18  
Glans Shaft Glans Shaft 
 
7 
 
6 
 
10 
 
2 
76 
 
28 
 
23 12 
1014 1063 1064 1083 
1159 men in Circumcision 
Arm 
2784 men randomized in circumcision trial        
(Bailey et al, 2007) 
1140 men in Control Arm 
2299 men consented with baseline HPV data 
485 men did not consent to HPV ancillary 
study or had no baseline HPV data 
63 no follow-up HPV 
data 
43 no follow-up HPV 
data 
1096 men with HPV follow-up 
data 
1097 men with HPV follow-up 
data 
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  Figure 4.2: Estimated Cumulative Incidence of High Viral Load infections over 24 months in Kenyan Men 
 HPV16 GLANS HPV16 SHAFT 
 
 
 
 
 
 
 
 
 
 
 
 
Number at Risk 
 
Circumcision Arm 
Control Arm 
 
 
 
1009 987 947 888 755 
1014 956 891 812 663 
 
 
 
 
 
1046 1028 982 920 784 
1063 1037 981 903 760 
 
 HPV18 GLANS HPV18 SHAFT 
 
 
 
 
 
 
 
 
 
 
 
 
Number at Risk 
 
Circumcision Arm 
Control Arm 
 
 
 
1057 1045 1004 945 815 
1064 1039 991 903 761 
 
 
 
 
 
 
1083 1071 1041 985 852 
1083 1068 1028 956 812 
 
 
Log rank P < 0.001 
Log rank P = 0.46 
Log rank P < 0.001 
Log rank P = 0.53 
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Figure 4.3: Estimated Clearance of Prevalent High Viral Load HPV Infections by circumcision status in Kenyan Men 
 HPV16 GLANS  HPV16 SHAFT  
 
 
 
 
 
 
 
 
 
 
 
 
 
Number of 
Prevalent HPV 
Infections  
 
Circumcision Arm 
Control Arm 
 
 
 
35 7 2 0 - 
44 24 8 4 - 
 
 
 
 
 
 
5 0 0 0 - 
3 2 1 0 - 
 
 HPV18 GLANS HPV18 SHAFT 
 
 
 
 
 
 
 
 
 
 
 
 
Number of 
Prevalent HPV 
Infections  
 
 
Circumcision Arm 
Control Arm 
 
 
 
24 4 1 0 0 
16 8 4 1 0 
 
 
 
 
 
 
4 0 0 - - 
6 1 0 - - 
 
Log rank P = 0.006 
Log rank P = 0.125 
Log rank P = 0.036 
Log rank P = 0.055 
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 Figure 4.4: Estimated Clearance of Low Viral Load Prevalent HPV Infections by circumcision status in Kenyan Men 
 HPV16 GLANS  HPV16 SHAFT  
 
 
 
 
 
 
 
 
 
 
 
 
Number of 
Prevalent HPV 
Infections 
 
Circumcision 
Arm 
Control Arm 
 
 
 
 
 
33 0 0 - 
32 4 1 - 
 
 
 
 
 
34 5 0 0 
25 2 1 0 
 
 HPV18 GLANS HPV18 SHAFT 
 
 
 
 
 
 
 
 
 
 
 
Number of 
Prevalent HPV 
Infections 
 
Circumcision 
Arm 
Control Arm 
 
 
 
 
13 1 0 - 
 7 1 0 - 
 
 
 
8 0 0 - 
6 0 0 - 
 
Log rank P = 0.387 Log rank P = 0.440 
Log rank P = 0.223 
Log rank P = 0.033 
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 Table 4.1: Baseline Characteristics by Intervention Treatment Arm 
 Circumcision Arm (N= 1096*) Control Arm (N= 1097*) 
Participant Characteristics
 †
   
Age (years) 20(19-22; 18-28; 1096) 20(19-22; 17-24; 1097) 
Education level 
     Less than secondary 
     Any secondary or above 
 
372 (33.9) 
724 (66.1) 
 
391 (35.6) 
706 (64.4) 
Employment status 
     Employed and receiving a salary 
     Self-employed 
     Unemployed 
 
94   (8.6) 
303 (27.7) 
699 (63.8) 
 
98   (8.9) 
294 (26.8) 
705 (64.3) 
Marital status 
     Not married (no live-in partner) 
     Not married (with live-in partner) 
     Married (not living with wife) 
     Married (living with wife) 
 
1024 (93.8) 
7 (0.6) 
5 (0.5) 
56 (5.1) 
 
1018 (93.2) 
7 (0.6) 
15 (1.4) 
52 (4.8) 
Number of partners over lifetime 4 (3-7; 1-120; 1004) 4 (3-7; 1-86; 1016) 
Number of sexual partners in previous 6 months 
     0 
     1 
     2+ 
 
137 (12.5) 
472 (43.2) 
484 (44.3) 
 
136 (12.4) 
472 (44.1) 
475 (43.5) 
Used a condom with intercourse in previous 6 months 
     Always 
     Inconsistent 
     Never 
 
210 (21.9) 
511 (53.3) 
238 (24.8) 
 
208 (21.7) 
500 (52.1) 
251 (26.2) 
Herpes simplex virus 2 
     Positive 
     Negative 
 
287 (27.3) 
764 (72.7) 
 
278 (26.5) 
771 (73.5) 
Trichomonas vaginalis 
     Positive 
     Negative 
 
21   (1.9) 
1064 (98.1) 
 
24   (2.2) 
1059 (97.8) 
Neisseria gonorrhoeae 
     Positive 
     Negative 
 
30   (2.8) 
1053 (97.2) 
 
17   (1.6) 
1066 (98.4) 
Chlamydia trachomatis 
     Positive 
     Negative 
 
57   (5.3) 
1025 (94.7) 
 
42   (3.9) 
1041 (96.1) 
Bathing frequency 
    Less than daily 
    Daily 
 
23   (2.1) 
1063 (97.9) 
 
22   (2.0) 
1062 (98.0) 
4
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*This table examines baseline characteristics in men with HPV follow-up data randomized to the circumcision and control arms 
† 
Data are median (IQR; range; n) for continuous data, or n (%) for categorical data. Numbers and percentages may not sum up to totals 
due to missing values and rounding. 
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Table 4.2: Effect of circumcision on incident high viral load HPV16 and HPV18 infections over 24 months in Kenyan 
Men 
 
     HPV 
 Type 
Site Treatment 
Arm 
All Samples Beta-globin Positive Samples 
Incident 
High VL 
Infections* 
Perso
n  
Years 
HR  (95% CI) † 
Incident High 
VL 
Infections* 
Person  
Years 
HR (95% CI) † 
HPV 16 
Glans Circumcision 26 1386.7 0.32 (0.20-0.49) 19 875.7 
0.31 (0.18 – 
0.50) 
Control 83 1366.1 1 72 976.0 1 
Shaft 
Circumcision 18 1443.8 0.79 (0.42 -1.45) 9 689.4 0.76 (0.31 -1.76) 
Control 24 1481.1 1 13 703.4 1 
HPV 18 
Glans Circumcision 22 1473.0 
0.34 (0.21 – 
0.54) 15 902.6 0.40 (0.21 -0.70) 
Control 66 1486.8 1 45 1055.4 1 
Shaft Circumcision 21 1521.8 
0.87 (0.48 – 
1.54) 11 725.1 0.67 (0.31 -1.42) 
Control 26 1539.9 1 17 719.7 1 
 
* Incidence was defined as the first type-specific HPV-positive result in men who were negative for that HPV type at the same anatomical 
site at baseline. High viral load (VL) was defined as >250 copies/scrape for the given HPV type. 
† Hazard Ratio (HR) comparing the risk of incident high viral load infections in circumcision versus control arm. 
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Table 4.3:  Association between circumcision and prevalence of high versus low viral load at detection of incident 
HPV infections 
 
     HPV 
Type 
Site Treatment 
Arm 
All Samples Beta-globin Positive Samples 
Incident HPV  
High VL/ Low 
VL* 
PR (95% CI) 
†
 
Incident HPV  
High VL/ Low 
VL*  
PR (95% CI)  
†
 
HPV 16 
Glans 
Circumcision 26 /43  0.70 (0.50 - 0.99) 19 /26 
0.72 (0.53 - 
0.98) 
Control  83 / 72  1 72 /51 1 
Shaft 
Circumcision 18 / 52  0.93 (0.55 - 1.57) 9 / 22 
0.92 (0.45 – 
1.86) 
Control  24 / 62  1 13 /28  1 
HPV 18 
Glans 
Circumcision 22 /24 0.59 (0.43 – 0.82) 15/16 0.59 (0.40 -0.87) 
Control  66 /16  1 45/10  1 
Shaft 
Circumcision 21 / 6  1.20 (0.88 – 1.62) 11 / 3  1.25 (0.84 -1.86) 
Control  26 /14 1 17/10 1 
 
*
 
Incidence was defined as the first type-specific HPV-positive result in men who were negative for that HPV type at the same anatomical 
site at baseline. High viral load (VL) was defined as >250 copies/scrape; low viral load was defined as  250 copies/scrape for the given 
HPV type.  
†
 Prevalence Ratio (PR) comparing the prevalence of high versus low viral load at HPV detection in men with incident HPV infections in 
the circumcision versus control arm. 
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Table 4.4: Clearance of baseline prevalent infections by circumcision status and HPV viral load in Kenyan Men 
Site 
Viral 
Load
†
 
Treatment 
Arm 
Cleared 
infections n/N* 
 
Person 
Years 
HR for 
Clearance 
(95% CI) 
‡
 
Estimated Risk of HPV Persistence  
(95% CI) 
††
 
6 months 12 months 
HPV16  Infections 
Glans 
High  
Circumcision 35/ 35 14.4 1.46 (0.91 -2.32) 0.20 (0.09 -0.34)** 0.06 (0.01-0.17) 
Control  40/44 23.8 1 0.55 (0.39 -0.68)** 0.18 (0.09-0.31) 
Low  
Circumcision 33/33 9.2 1.31 (0.68 -1.89) 0 0 
Control  31/32 9.3 1 0.13 (0.04 -0.26) 0.03 (0.00 -0.14) 
Shaft  
High  
Circumcision 5/5 1.3 4.34 (0.67 -84.9) 0 0 
Control  3/3 2.2 1 0.67 (0.05 -0.94) 0.33 (0.01 -0.77) 
Low  
Circumcision 34/34 12.1 0.82 (0.49 -1.42) 0.15 (0.05 -0.28) 0 
Control  25/25 7.8 1 0.08 (0.01 -0.22) 0.04 (0.00 - 0.17) 
HPV18  Infections 
Glans 
High  
Circumcision 24/24 9.1 2.02 (1.02- 4.08) 0.17 (0.05 -0.34)** 0.04 (0.00 -0.18) 
Control  16/16 10.8 1 0.50 (0.35 -0.71)** 0.25 (0.08 -0.47) 
Low  
Circumcision 13/13 3.9 1.79 (0.70 -5.15) 0.08 (0.00 -0.29) 0 
Control  7/7 2.5 1 0.14 (0.01 -0.46) 0 
Shaft  
High  
Circumcision 4/4 1.0 4.33 (0.78 -33.3) 0 0 
Control  6/6 2.3 1 0.15 (0.01 -0.52) 0 
Low  
Circumcision 8/8 2.5 0.34 (0.10 -1.12) 0 0 
Control  6/6 1.5 1 0 0 
†
 High viral load was defined as >250 copies/scrape; low viral load was defined as  250 copies/scrape for the given HPV type.  
*Clearance was defined as an HPV-negative result in participants who were positive for that given HPV type at baseline; n= number of 
cleared HPV infections; N=total number of HPV infections present at baseline. 
‡
 Hazard Ratio (HR) comparing clearance of prevalent HPV infections at baseline in circumcision versus control arm over 24 months. 
††
Persistence was defined as an HPV-positive result in participants who were positive for that given HPV type at the same anatomical site in 
the previous visit. Estimates for risks of persistence and duration since baseline visit were obtained from Kaplan Meier graphs. **P-value 
<0.05 for z-score test comparing estimated risk of HPV persistence in circumcision versus control arm.
4
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CHAPTER 5  
ASSOCIATION BETWEEN PENILE HPV VIRAL LOAD AND HPV CLEARANCE IN 
UNCIRCUMCISED KENYAN MEN 
 
Overview 
Higher viral loads of high-risk HPV infections in women are associated with lower 
HPV clearance in comparison to lower viral loads; however, the association between 
HPV viral load and HPV clearance has not been explored among penile HPV infections. 
Penile swabs from glans and shaft sites were collected from men enrolled in the control 
arm of a randomized controlled trial (RCT) of male circumcision in Kisumu, Kenya. 
GP5+/6+ PCR was used to identify HPV DNA types. HPV viral load was measured with 
LightCyler real-time PCR and classified as high (>250 copies/scrape) or low (250 
copies/scrape). Most high and low viral load HPV16 or HPV18 infections cleared within 
6 months of HPV detection. The hazard of HPV16 clearance at 6 months after first 
HPV16 detection was found to be lower for high versus low viral load incident infections 
in the glans [adjusted hazard ratio (aHR) =0.58 (95%confidence interval, 0.36-0.93)]. 
The 6-month risk of HPV16 persistence was greater for high versus low viral load 
infections in the glans for both incident infections [Risk Ratio (RR) = 3.28 (1.29-8.36)] 
and prevalent infections detected at baseline [RR =4.36 (1.68-11.35)]. HPV16 and 
HPV18 clearance in the shaft was comparable for high and low viral load infections. The 
lower HPV16 clearance rate of high versus low viral load infections in the glans could 
possibly be associated with an increased risk of penile SCC development, and may 
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explain the higher incidence of penile carcinomas observed in the glans than any other 
penile site. The lower HPV16 clearance in men with high viral load infections may also 
explain the reported increase in HPV16 transmission to their female partners in 
comparison to men with low viral load. 
 
Introduction 
Persistent infections with human papillomavirus (HPV) high-risk types 16 and 18 
are causes of approximately 70% of cervical cancer in women and approximately half of 
penile squamous cell carcinomas (SCC) in men, particularly basaloid and warty SCC 
types (1, 9, 10, 33). Women with higher HPV16 or HPV18 viral loads are more likely to 
have persistent infections and to progress to high grade cervical intraepithelial 
neoplasia (CIN) than those with lower viral loads (11-17). The association between HPV 
viral load and HPV clearance has not yet been examined in penile HPV infections in 
men; higher HPV16 or HPV18 viral loads could possibly be associated with lower HPV 
clearance and increased progression to penile SCC.  
Higher HPV16 or HPV18 viral loads in men are associated with an increased 
prevalence of flat penile lesions and greater HPV type concordance with female 
partners in comparison to lower viral loads (2, 52, 53). As a result, higher HPV viral load 
in men is suggested to be associated with increased HPV transmission to their female 
partners in comparison to lower HPV viral load (2). It is believed that lower HPV 
clearance of high versus low viral load HPV infections in men may enhance HPV 
transmission to their female partners, however, the association between higher HPV 
viral load and lower HPV clearance in penile HPV infections is yet to be established. 
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We present the results of a longitudinal study examining the association between 
viral load and the clearance of penile HPV infection in uncircumcised men in Kisumu, 
Kenya. We examine penile HPV viral load measured at first detection of HPV16 or 
HPV18 infections in the glans and shaft sites and the subsequent rate of HPV clearance 
over a study period of 24 months. The association between HPV viral load and HPV 
clearance is examined separately for incident infections and infections detected at 
baseline (prevalent infections).  We have previously examined the effect of male 
circumcision on HPV viral load, which included men from this study in the control group 
(55); here we examine the association between penile HPV viral load and the clearance 
of penile HPV infections among these uncircumcised men. 
 
Methods 
 
Study population and enrollment  
Uncircumcised men were screened between February 4, 2002 and September 6, 
2005 in Kisumu, Kenya to participate in an RCT of male circumcision (5). The main aim of 
the trial was to determine the effectiveness of male circumcision in reducing HIV incidence. 
Baseline study inclusion criteria included being uncircumcised, aged 18-24, HIV negative, 
sexually active within the past 12 months and having blood hemoglobin ≥ 90 g/l. Study 
participants were recruited from STI clinics, workplaces and community organizations.  The 
study protocol was approved by Institutional Review Boards of the Universities of Illinois at 
Chicago, Manitoba, Nairobi and North Carolina; RTI International and VU University 
Medical Center. 
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This analysis includes men from the control arm of the RCT who consented to the 
collection of penile exfoliated cells and their shipment overseas for HPV DNA and HPV viral 
load testing. Of the 2784 uncircumcised men enrolled in the RCT, 2299 (83%) consented to 
provide penile swab samples and had baseline HPV data; 1159 men were randomized to 
immediate circumcision and 1140 to the control arm. Eligibility for inclusion in clearance 
analyses was determined for each HPV type (HPV16 or 18) and anatomical site (glans or 
shaft) separately. Participants assigned to the control arm who: i) had no HPV follow-up 
data; ii) were HPV16 or HPV18-negative throughout follow-up; iii) had their first HPV16 or 
HPV18-positive result at the last study visit; or iv) had missing HPV viral load data were 
excluded from clearance analyses for that specific HPV type and anatomical site (Figure 
5.1.). 
Follow-up and specimen collection 
Participant follow-up visits were scheduled at 6 month intervals for a period of 24 
months. A standardized questionnaire on sociodemographic characteristics and sexual 
behavior was administered by a trained male interviewer at each visit (5). Penile exfoliated 
cell specimens were collected by a trained physician or clinical officer at each study visit 
(18). Samples were collected from two anatomical sites: (i) penile shaft and external 
foreskin (shaft specimen); and (ii) glans, coronal sulcus, and the internal tissue of the 
foreskin (glans specimen). Two pre-wetted type 3 Dacron swabs were used to collect 
penile exfoliated cells from the two separate anatomical sites. Each swab was placed in a 
sterile 15 ml centrifuge tubes with 2-mL of 0.01 mol/L Tris-HCl 7.4 pH buffer with the 
participant’s identification (ID) number, the visit number, and anatomical site of specimen 
(glans or shaft). Each sample was centrifuged at high speed for 10 minutes in the clinic 
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laboratory on the same day of collection. Excess Tris-HCl buffer was discarded using a 
Pasteur pipette, and the pellet was resuspended in the same volume of 0.01mol/L of Tris-
HCl buffer and vortexed. Diluted cell pellets were frozen and stored at -75°C. All samples 
were transported via Fedex in a liquid nitrogen dry shipper from Kisumu to the Department 
of Pathology at VU Medical Center in Amsterdam, Netherlands, for HPV DNA testing. 
 
HPV DNA, HIV and STI Testing 
DNA was isolated from penile exfoliated cell samples using NucleoSpin 96 
Tissue kit (Macherey-Nagel, Germany) and a Microlab Star robotic system (Hamilton, 
Germany) according to manufacturers’ instructions. Presence of human DNA was 
evaluated by beta-globin specific PCR, followed by agrose gel electrophoresis (19, 
20).HPV positivity was assessed by GP5+/6+ PCR followed by hybridization of PCR 
products using an enzyme immunoassay readout with two HPV oligoprobe cocktail 
probes that detect 44 HPV types (high-risk: HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 
58, 59, 66, 68; low-risk: HPV6, 11, 26, 30, 32, 34, 40, 42, 43, 44, 53, 54, 55, 57, 61, 64, 
67, 69, 70, 71, 72, 73, 81, 82, 83, 84,cand85, 86, cand89, JC9710). Subsequent HPV 
genotyping was performed by reverse line blot (RLB) hybridization of PCR products (19, 
20). 
HIV testing was performed at each visit using two HIV antibody rapid tests 
(Determine, Abbott Diagnostic Division, Hoofddorp, Netherlands; and Unigold, Trinity 
Biotech, Wicklow, Ireland), and confirmed by double ELISA (Adaltis, Montreal, Canada; 
Trinity Biotech, Wicklow, Ireland) at the University of Nairobi. A physician or clinical officer 
conducted a genital exam during which a swab (if symptomatic) or urine sample were 
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collected for polymerase chain reaction (PCR) detection of C. trachomatis and N. 
gonorrhea (Roche Diagnostics). Blood was collected for herpes simplex virus type 2 (HSV-
2; enzyme-linked immunosorbent assay (ELISA) [Kalon]).  
 
HPV Viral Load Testing 
HPV DNA viral load testing was performed on penile exfoliated cell samples that 
contained HPV16 or HPV18 using a real time PCR assay and a LightCycler instrument 
(Roche, Mannheim, Germany) (21). DNA extraction and purification were conducted 
according manufacturer instructions using 100 μl of the remaining cell suspensions. All 
samples were run in duplicate in the same run and resulting viral load values were 
averaged. Dilutions of cloned HPV DNA were used to determine the standard curve for the 
HPV target. To calculate the number of copies per sample, the amount of HPV DNA in one 
femtogram was multiplied by the dilution factor and divided by the weight of the cloned 
pHPV viral genome. HPV viral load was categorized as low (250 copies/scrape) or high 
(>250 copies/scrape) for each HPV16 and HPV18 infection at each anatomical site. The 
250 copies/scrape cut-point for high versus low viral load was chosen because of its 
significance in previous HPV viral load studies; men with high viral load values (>250 
copies/scrape) have been found to have a higher prevalence of flat penile lesions and 
increased HPV type concordance with female partners (2, 53).  
Statistical Analyses 
The distribution of participant characteristics by HPV16 or HPV18 viral load (high or 
low) was examined for infections prevalent at baseline. For these analyses, HPV viral load 
results from the glans and shaft samples were combined; high viral load was defined as 
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>250 copies/scrape in the glans or shaft, and low viral load was defined as  250 
copies/scrape in both the glans and shaft. Baseline characteristics examined included age, 
education, employment, marital status, bathing frequency, number of sexual partners and 
condom use in the previous 6 months.  
HPV clearance analyses were performed separately for incident and prevalent 
HPV16 or HPV18 infections. We also examined HPV clearance separately for glans and 
shaft infections since HPV clearance has been shown to vary by anatomical site (8) . 
For each participant, only the first detected HPV16 or HPV18 infection (incident or 
prevalent) at each anatomical site (glans or shaft) was included in clearance analyses. 
Time-to-clearance since HPV detection was calculated starting at the visit date of first 
HPV detection; for prevalent infections the start date was baseline, and for incident 
infections it was the visit date of first HPV detection for each HPV type at each 
anatomical site. Clearance was assumed to occur at the mid-point between the last 
HPV-positive result and the first subsequent HPV-negative result. Men were censored 
at their last observed visit if they remained HPV positive for the same HPV type at the 
same anatomical site for each observed consecutive visit.  
 HPV viral load measurements at first detection of HPV16 or HPV18 prevalent or 
incident infections were used to classify the infections as high (>250 copies/scrape) or 
low ( 250 copies/scrape) viral load infections.  For all the clearance analyses, HPV 
viral load was analyzed as a time-fixed exposure; few HPV16 or HPV18 infections 
(8.4% overall) were observed to change viral load groups during follow-up. The actual 
circumcision status of eligible men at each visit was reviewed to verify that they were 
uncircumcised during HPV detection and clearance; 12 men assigned to the control arm 
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were circumcised later in the study, however, in each case circumcision was performed 
after clearance of HPV infections so these men were included in clearance analyses. 
The Kaplan-Meier method was used to estimate the cumulative incidence for 
clearance of high versus low viral load HPV infections at 6 months (6-month risk) after 
HPV detection. Risk ratio estimates were calculated to compare 6-month and 12-month 
clearance risk estimates of high versus low viral load infections (51). Potential 
confounders of the association between HPV viral load and HPV clearance were 
identified from the literature, and analyzed using a DAG (50). Confounders identified 
and included in Cox regression models were: HIV infection, condom use, number of sex 
partners, bathing frequency, infection with multiple HPV types, educational attainment, 
and infection with other STIs (HSV-2, Trichomonas vaginalis, Chlamydia trachomatis 
and Neisseria gonorrhoeae). Adjusted hazard ratios (aHRs) comparing the clearance 
hazard at 6 months for high versus low viral load HPV infections were estimated for 
each HPV type and anatomical site. HRs at 6-months after HPV detection could not be 
obtained in cases where all high viral load or low viral load infections cleared by 6 
months after HPV detection.  An interaction term between the HPV viral load group and 
time-to-clearance was included in all the Cox regression models to account for non-
proportional hazards in clearance of high and low viral load HPV infections. Sensitivity 
analyses for clearance of prevalent and incident infections were performed by restricting 
analyses to samples that tested positive for the presence of human DNA with the beta-
globin test.   
 
 58 
 
Results 
Of  the 1140 men randomized to the control arm of the main RCT, 1097 (96.2%) 
men had follow-up HPV data (Figure 5.I). Eligibility for inclusion in clearance analyses 
was determined separately for each HPV type and for each anatomical site. Of the 
samples with HPV-positive results, similar proportions were excluded for missing 
HPV16 or HPV18 viral HPV load results [HPV16 glans= 7(3.1%), HPV16 shaft 
=6(5.3%), HPV18 glans=8 (7.4%) and HPV18 shaft =2(3.9%)]. Also, similar proportions 
of incident HPV infections were observed at the 24-month visit (last study visit) and thus 
excluded from clearance analyses for each HPV type and anatomical site [HPV16 glans 
=37(23.9%), HPV16 shaft =17(19.8%), HPV18 glans= 17 (20.2%) and HPV18 shaft = 
11(27.5%)] (Figure 5.I). 
 
Distribution of Participant characteristics by HPV viral load at baseline 
Of the 2299 uncircumcised men enrolled in the RCT with baseline HPV results, 
239 (10%) men were HPV16-positive and 103 (5%) were HPV18-positive in either the 
glans or shaft sites and had HPV viral load data at baseline (Table 5.1). Few men had 
infections in both the glans and shaft [25(11%) for HPV16; 8 (8%) for HPV18], and in 
each case the HPV viral load category was the same for both anatomical sites. Infection 
with multiple HPV types at baseline was associated with high versus low HPV viral load 
for both HPV16 and HPV18 prevalent infections. For HPV18 prevalent infections, the 
presence of sexually transmitted infections (HSV-2, Trichomonas vaginalis, Chlamydia 
trachomatis or Neisseria gonorrhoeae) was associated with high versus low viral load, 
however this association was not observed for HPV16 prevalent infections. Men with 
high versus low viral HPV16 or HPV18 viral load appeared to have similar distributions 
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of age, employment status, educational attainment, number of sexual partners and 
condom use in previous 6 months, marital status and bathing frequency at baseline. 
 
HPV Viral load and Clearance of Penile HPV Infections Prevalent at Baseline 
 At baseline, a greater proportion of high viral load HPV infections was detected in 
the glans for both HPV16 [57.9% (N=44)] and HPV18 [69.6% (N=16)], than in the shaft 
[HPV16 =10.7% (N=28); HPV18 =50.0% (N=6)] (Table 5.2). All HPV18 infections and 
most HPV16 (93.4%) infections detected at the baseline visit in the glans or shaft 
cleared during follow-up (Figure 5.2). In the glans, the 6-month risk of HPV persistence 
was greater in high versus low viral load infections for HPV16 [RR =4.36 (1.68-11.35)] 
(Table 5.2).Less precise results were obtained for the 6-month risk of HPV persistence 
for high and low viral load HPV16 infections in the shaft [RR = 3.50 (0.53 - 22.92)]. 
Results suggest that the hazard of HPV16 clearance at 6 months after baseline [aHR = 
0.61 (0.34-1.09)] was lower for high versus low HPV16 viral load infections in the glans 
after adjustment for possible confounders. Sensitivity analyses restricted to HPV 16 
prevalent infections in the glans that were β-globin positive (52.6%) found weaker and 
less precise results [aHR = 0.88 (0.34-2.36)] for clearance of high versus low viral load 
HPV16 prevalent infections. 
 
HPV Viral Load and Clearance of Incident Penile HPV Infections 
Of the incident HPV infections observed, a greater proportion of high viral load 
infections was detected in the glans for both HPV16 [55.1% (N=65)] and HPV18 [80.1% 
(N=54)] than in the shaft [HPV16 =29.0% (N=20); HPV18 =65.5% (N=19)] (Table 5.2). 
Most of the incident HPV16 (89.1%) or HPV 18 (85.4%) infections in the glans or shaft 
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cleared during follow-up (Figure 5.3). The 6-month risk of HPV16 persistence was 
greater for high versus low HPV16 viral load infections in the glans [6-month RR = 3.28 
(1.29 - 8.36)] (Table 5.2). The hazard of HPV16 clearance at 6 months after HPV 
detection [aHR = 0.58 (0.36-0.93)] was lower for high versus low viral load HPV16 
infections in the glans after adjustment for possible confounders. In the shaft, the 
hazard of HPV16 clearance at 6 months after HPV detection was similar for high and 
low viral load HPV16 infections [aHR = 0.83 (0.34 -1.65)].  For HPV 18 incident 
infections, the 6-month risk of HPV persistence was similar for high and low viral load 
infections in the glans [6-month risk = 1.78 (0.21 -14.90)] (Table 5.2). Sensitivity 
analyses restricted to HPV 16 incident infections that were β-globin positive in the glans 
(59.3%) or shaft (50.7%) found less precise results as the main analyses [aHR glans = 
0.52 (0.22- 1.15); aHR shaft = 0.32 (0.04- 1.69)] for the clearance of high versus low 
viral load infections. 
 
Discussion 
Among uncircumcised Kenyan men, the clearance rate of HPV16 incident 
infections in the glans was found to be lower for high versus low HPV viral load 
infections at 6 months after HPV16 detection. For both prevalent and incident infections, 
the 6-month risk of HPV16 persistence was greater for higher than lower HPV viral load 
infections in the glans. A greater proportion of high viral load infections was observed in 
the glans than the shaft for both prevalent and incident HPV16 or HPV 18 infections. In 
the shaft, the risk of HPV16 or HPV18 persistence to 6 months after detection was 
similar for high and low viral load infections. 
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This is the first study, to our knowledge,  to examine the association between 
penile HPV viral load and subsequent HPV clearance. Direct comparison of our results 
to those from HPV viral load studies in women is complicated by the differences in 
detected HPV types, viral load categories and the different cervical cytology profiles 
(normal versus abnormal) across studies. One study in French women with normal 
cytology found that those with higher viral loads of high-risk HPV types (≥10pg/ml) at 
baseline had lower HPV clearance than women with lower viral loads [risk ratio= 0.65 
(0.44-0.94)] (43). Another study in Danish women with abnormal cytology found that 
those with the 50% lowest viral load had an increased risk of HPV16 clearance [OR 
=5.0 (1.7 -15)] (56). A study in Korean women who underwent conization treatment for 
CIN found that higher pre-cone HPV viral load (≥ 100 RLU/PC) was the only risk factor 
for HPV persistence after conization [OR =5.75 (1.08 -30.52)] (42).Two studies found 
conflicting results in examining a dose-response relationship between HPV viral load 
and HPV clearance in women with normal cytology; one in Colombian women found no 
dose-response relationship whereas the other in Canadian women found that HPV 
clearance was greater in women with lower tertiles as compared to higher tertiles of 
HPV16 or HPV 18 viral load [HR =2.4 (1.8-6.2)] (12, 57). Thus, results on HPV viral load 
and HPV clearance in women are inconclusive, but results from several studies 
suggesting that high HPV viral load is associated with lower HPV clearance, are similar 
to our findings in Kenyan men (12, 42, 43, 56, 57).  
The lower HPV clearance observed in cases of high HPV viral load infections 
may be explained by the greater number of virus-infected cells the immune system may 
have to eliminate as compared to low viral HPV viral load infections (49). Alternatively, 
 62 
 
lower clearance of high viral load infections may reflect a weaker immune response to 
the HPV virus and virus-infected cells (49). Our baseline risk factor analyses found that 
high HPV16 or HPV18 viral load is associated with a greater presence of STIs or 
infections with multiple HPV types; this suggests that high HPV viral loads are possibly 
more likely to occur in men with weaker immune systems in comparison to low HPV 
viral loads. 
We also found a greater proportion of high viral load infections in glans than the 
shaft for both HPV16 and HPV18 incident and prevalent infections. These findings are 
different from results of a cross-sectional study of men in the United States (Arizona and 
Florida) that found higher HPV viral load in the shaft than any other penile site (58). This 
difference is likely due to the fact that 86% of men in the U.S. cross-sectional study 
were circumcised, whereas all the men in our study were uncircumcised during 
detection of HPV infection and HPV clearance.  In uncircumcised men, the moist 
subpreputial cavity that surrounds the glans is believed to promote HPV survival and 
HPV viral replication (39). 
Main strengths of this study include the extensive longitudinal data on HPV viral 
load, quantitative HPV viral load measurements by real time PCR, and the separate 
evaluation of samples from the glans and the shaft anatomical sites. Our main study 
limitation is that HPV viral load measurements were not normalized to account for number 
of cells in each swab sample (viral load copies/cell). However, the copies/scrape units have 
been previously used to show the associations between high HPV viral load (>250 
copies/scrape) and higher prevalence of flat penile lesions as well as increased HPV type 
concordance with female partners (2, 53). We also observed fairly low beta-globin positivity 
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in our samples (56.7% in glans and 48.4% in shaft samples). It is possible that HPV viral 
load measurements in this study may be underestimated, although similar prevalences of 
beta-globin positivity have been observed among men (7). Sensitivity analyses restricted to 
beta-globin positive samples generated less precise results, however estimates suggested 
that high versus low viral load HPV infections were associated with lower HPV clearance as 
observed in the main analyses. Our analyses also examined HPV viral load measurements 
every 6 months; it is possible that different time intervals between visits could produce 
different results for the association between HPV viral load and clearance. The challenge of 
defining HPV clearance and persistence based on study visits is still an unresolved issue in 
HPV research, however, the 6–month time interval used in this study is comparable to the 
reported average durations of penile HPV infection in men (range 5.9 -7.5 months) (31, 48). 
Lastly, the interpretation of our results is limited by the inability to distinguish between 
integrated and episomal HPV DNA; studies in women have shown that the physical state of 
viral DNA is important in understanding the association between HPV viral load, HPV 
clearance and progression to CIN (59-61). Future research distinguishing integrated and 
episomal HPV DNA by examining the ratio of expressed E2 and E6 HPV genes is needed 
to further understand the association between detected HPV viral load and HPV clearance.  
High HPV16 viral load in the glans is associated with lower HPV16 clearance and 
thus, could possibly be associated with an increased risk of penile squamous cell 
carcinoma development in the glans in comparison to low HPV16 viral load. The 
majority of anatomically classified penile carcinomas are reported to occur in the glans 
(62%) than any other penile site; this may be in-part due to the lower clearance of high 
versus low viral load HPV infections observed in the glans but not in the shaft (62). Our 
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results may also explain why men with higher HPV16 viral loads may have greater 
HPV16 transmission to their female partners than those with lower viral loads; the 
longer duration of infection for high versus low viral load infections in men could 
increase the possibility of HPV transmission to their female partners (2). The 
generalizability of our results is limited to uncircumcised men since circumcision has 
been found to independently enhance HPV clearance; future research is needed to 
examine if the association between HPV viral load and HPV clearance exists in 
circumcised men (7, 8). 
In conclusion, this study found that most HPV16 or HPV18 infections in the glans or 
shaft cleared within 6 months of first detection in young uncircumcised men. For both 
prevalent and incident infections, the 6-month risk of HPV16 persistence was greater for 
high viral load than low viral load infections in the glans. High viral load of HPV16 incident 
infections in the glans was associated with lower HPV clearance at 6 months after HPV 
detection in comparison to low HPV16 viral load, and thus, could possibly be associated 
with an increased risk of penile SCC development in uncircumcised men. Our results also 
provide further support for the suggested association between high HPV viral load in men 
and increased HPV transmission to their female partners. 
  
 
Tables and Figures 
Figure 5.1:  Study flowchart of samples included in analyses of HPV viral load and HPV clearance 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HPV Types HPV 16  HPV 18  
Anatomic Sites Glans Shaft Glans Shaft 
Exclusion Criteria for Samples: 
1. HPV (-) throughout study 
2. First HPV(+) result at 24month (last) visit 
3. Missing Viral load 
 
859 
37 
7 
 
977 
17 
6 
 
982 
17 
8 
 
1043 
11 
2 
 
Total Samples included in Analyses 
          Prevalent HPV Infections 
          Incident  HPV Infections 
 
76 
118 
 
28 
69 
 
23 
67 
 
12 
29 
 1159 men in Circumcision Arm 
(239 men HPV16-positive, 103 men 
HPV18-positive at baseline with 
viral load data) 
 
 
 
 
 
 
2784 men randomized in male circumcision trial        
(Bailey et al, 2007) 
1140 men in Control Arm 
2299 men consented with baseline HPV data 
(239 men HPV16-positive, 103 men HPV18-positive at baseline with viral load data) 
 
 
 
 
 
 
485 men did not consent to HPV ancillary 
study or had no baseline HPV data 
1097 men with follow-up data 
43 men with no follow-up data  
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Figure 5.2: Estimated clearance of prevalent HPV infections by HPV Viral Load in uncircumcised Kenyan Men 
 HPV16 GLANS  HPV16 SHAFT  
 
 
 
 
 
 
 
 
 
 
 
 
High Viral Load 
Low Viral Load 
 
 
 
44 24 8 4 - 
32 4 1 0 - 
 
 
 
3 2 1 0 - 
25 3 2 0 - 
 
 HPV18 GLANS HPV18 SHAFT 
 
 
 
 
 
 
 
 
 
 
 
 
High Viral Load 
Low Viral Load 
 
 
 
16 8 4 1 0 
7 1 0 0 0 
 
 
 
 
 
6 1 0 - - 
6 0 0 - - 
 
 
Log rank P = 0.006 
Log rank P = 0.338 
Log rank P = 0.133 Log rank P = 0.077 
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Figure 5.3: Estimated clearance of incident HPV infections by HPV Viral Load in uncircumcised Kenyan Men 
 HPV16 GLANS  HPV16 SHAFT  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
High Viral Load 
Low Viral Load 
 
 
65 19 2 0 - 
53 4 1 0 - 
 
 
 
 
 
20 1 0 - - 
49 6 0 - - 
 
 HPV18 GLANS HPV18 SHAFT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
High Viral Load 
Low Viral Load 
 
 
 
54 13 2 0 - 
13 0 0 0 - 
 
 
 
 
 
19 1 0 - - 
10 0 0 - - 
 
Log rank P = 0.012 Log rank P = 0.870 
Log rank P = 0.001 Log rank P = 0.606 
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Table 5.1: Participant characteristics, stratified by baseline HPV viral load for HPV types 16 and 18 in men in Kisumu, 
Kenya 
 HPV16 Prevalent Infections (N =239)* HPV18 Prevalent Infections (N=103)* 
Demographic characteristics† High HPV16 Viral 
Load
 a
 (N =109 ) 
Low HPV16 Viral  
Load 
a 
(N =130) 
High HPV18 Viral 
Load
 a
 (N =65) 
Low HPV18 Viral 
Load
 a
 (N =38) 
Age (years)  20 (19-21;18-24;109) 20 (19-22;18-24;130) 20 (19-22;18-24;65) 20 (20-22;18-24;38) 
Education level 
     Less than secondary 
     Any secondary or above 
 
40 (36.7) 
69 (63.3) 
 
55 (42.3) 
75 (57.7) 
 
23(35.4) 
42(64.6) 
 
15 (39.5) 
23 (60.5) 
Employment status 
     Employed and receiving a salary 
     Self-employed 
     Unemployed 
 
6 (5.5) 
38 (34.7) 
65 (59.6) 
 
7(5.4) 
41 (31.5) 
82 (63.1) 
 
7 (10.8) 
21 (32.3) 
37 (56.9) 
 
3 (7.9) 
12 (31.6) 
23 (60.5) 
Marital status 
     Not married (no live-in partner) 
     Married (not living with wife) 
     Married (living with wife) 
 
103 (95.4) 
2 (1.8) 
3 (2.8) 
 
125 (96.1) 
0 
5 (3.9) 
 
61 (93.8) 
4 (6.2) 
0 
 
34 (89.5) 
3 (7.9) 
0 
Infection with Multiple HPV types
 ‡ 
 
     Yes 
     No 
 
 74 (67.9)  
35 (32.1) 
 
75 (57.7) 
55 (42.3) 
 
 52 (80.0)  
13 (20.0) 
 
23 (60.5) 
15 (39.5) 
Infection with sexually transmitted infections 
§
 
     Positive 
     Negative 
 
32 (29.3) 
77 (70.7) 
 
45 (34.6) 
85 (65.4) 
 
 24 (36.9) 
41 (63.1) 
 
7 (18.4) 
31 (81.6) 
Number of partners in previous 6 months 
     0 
     1 
     2+ 
 
12 (11.1) 
41 (38.0) 
55 (50.9) 
 
12 (9.3) 
63 (48.8) 
54 (41.9) 
 
8 (12.3) 
27 (41.5) 
30 (46.2) 
 
4 (10.5) 
19 (50.0) 
15 (39.5) 
Used condom with intercourse in previous 6 
months 
     Always 
     Inconsistent 
     Never 
 
17 (17.5) 
54 (55.7) 
25 (25.7) 
 
32 (27.1) 
59 (50.0) 
27 (22.9) 
 
11 (18.6) 
33 (55.9) 
14 (23.7) 
 
5 (14.7) 
18 (52.9) 
11 (32.4) 
Bathing Frequency 
     Less than daily 
     Daily 
 
3 (2.8) 
105 (97.2) 
 
3 (2.3) 
127 (97.7) 
 
2 (3.1) 
63 (96.9) 
 
2 (5.3) 
36 (94.7) 
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*
 
This table includes only men with detected HPV16 DNA or HPV18 DNA at baseline. High viral load was defined as >250 copies/scrape in the 
glans or shaft. Low viral load was defined as  250 copies/scrape in the both the glans and shaft. Numbers and percentages may not sum up 
to totals due to missing values and rounding. 
† Data are median (IQR; range; n) for continuous data, or n (%) for categorical data.  
‡ 
Infection with multiple HPV types was defined as co-infection with at least one other HPV type 
§ 
Positive result for HSV-2, Trichomonas vaginalis, Chlamydia trachomatis or Neisseria gonorrhoea was examined.  
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Table 5.2: The association of penile HPV viral load and HPV clearance in uncircumcised Kenyan Men 
HPV 
Type 
Site 
Viral 
Load
†
 
Cleared 
infection
s (n/N*) 
 
 
Person-
Years 
Estimated 6-month Risk of 
HPV Persistence (95% CI) 
††
 
Estimated 6-month RR 
of HPV Persistence 
(95% CI) 
††
 
Adjusted HR (aHR) for 
clearance at 6-months 
(95% CI) 
‡
 
Prevalent  HPV infections  
HPV16 
Glans 
High 40/44 28.88 0.56 (0.40-0.69) 4.36 (1.68 – 11.35) 0.61 (0.34-1.09) 
Low  31/32 11.61 0.13 (0.01-0.24) 1 1 
Shaft 
High 3/3 2.19 0.67 (0.13-0.99) 8.34 (1.76- 39.36) 
--  
¶
 
Low  25/25 7.81 0.08 (0.01-0.19) 1 
HPV 
18 
Glans 
High 16/16 10.75 0.50 (0.26-0.75) 3.50 (0.53- 22.92) 
--  
¶
 
Low  7/7 2.47 0.14 (0.03-0.40) 1 
Shaft 
High 6/6 2.28 0.17 (0.00-0.46) 
--  
¶
 --  
¶
 
Low  6/6 1.53 0 
Incident  HPV infections    
HPV16 
Glans 
High 52/65 27.20 0.34 (0.22-0.45) 3.28 (1.29 – 8.36) 0.58 (0.36-0.93) 
Low  45/53 14.96 0.10 (0.01-0.19) 1 1 
Shaft 
High 20/20 5.86 0.09 (0.01-0.17) 1.78 (0.21 -14.90) 0.83 (0.34 -1.65) 
Low  42/49 13.11 0.05 (0.00-0.15) 1 1 
HPV 
18 
Glans 
High 45/54 19.92 0.30 (0.17-0.42) 
--  
¶
 --  
¶
 
Low  11/13 2.56 0 
Shaft 
High 17/19 5.14 0.06 (0.00-0.18) 
--  
¶
 --  
¶
 
Low  9/10 2.36 0 
†
High viral load was defined as >250 copies/scrape; low viral load was defined as  250 copies/scrape 
* Clearance was defined as an HPV-negative result in participants who were positive for that given HPV type at previous visit; n= number of 
cleared HPV infections; N=total number of HPV infections observed 
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‡ 
Adjusted Hazard Ratio (aHR) comparing clearance of high versus low viral load infections at 6 months after infection. HR adjusted for 
infection with multiple HPV types, number of sex partners, bathing frequency, education, HIV infection, infection with other STIs and condom 
use. 
 
††
Persistence was defined as an HPV-positive result in participants who were positive for that given HPV type in the previous visit. Estimates 
for risk and RR of persistent infections at 6 months since infection were derived from Kaplan Meier survival estimates 
¶
 Risk Ratio (RR) or adjusted hazard ratio (aHR) could not be obtained because all HPV infections in one group had cleared at 6 months after 
HPV detection
7
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CHAPTER 6 
 CONCLUSION 
 
The first aim of this dissertation was to examine the association between male 
circumcision and HPV viral load in men aged 18-24 in Kisumu, Kenya. As hypothesized, 
we found that male circumcision reduces acquisition of high viral load infections for both 
HPV16 [HR =0.32(0.20-0.49)] and HPV18 [HR=0.34(0.21-0.54)] in the glans. Among 
men with incident infections in the glans, prevalence of high versus low viral load at 
HPV detection was lower in the circumcision than control arm for HPV16 [ PR =0.70 
(0.50-0.99)] and HPV18 [PR=0.59(0.43-0.82)]. Although overall HR estimates 
suggested that clearance of baseline prevalent high and low infections was comparable 
in circumcision and control arm, the risk of persistence to 6 months after baseline for 
high viral load infections was lower in the circumcision than control arm in the glans for 
HPV16 and HPV18. Interestingly, we found that the risk of persistence to 6 and 12 
months for prevalent infections detected at baseline was similar in circumcised men with 
high HPV viral load and uncircumcised men with low HPV viral load, for both HPV types 
and anatomical sites.  
High HPV viral load in men is suggested to be associated with increased HPV 
transmission to female partners (2). Also, fewer HPV infections and lower HPV viral 
loads have been reported in female partners of circumcised than uncircumcised men  
(40, 54). Findings from this analysis suggest that male circumcision could potentially 
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reduce HPV transmission to women by reducing acquisition and enhancing clearance of 
high HPV viral load infections in men.  Voluntary Medical Male Circumcision for HIV 
prevention is currently being promoted in East and Southern Africa, our findings suggest 
that male circumcision may also be beneficial in decreasing HPV transmission from 
men to women (63). 
The second aim of this dissertation was to examine the association between viral 
load at HPV detection and HPV clearance in uncircumcised men. This analysis was 
conducted only in uncircumcised men since male circumcision has been shown to 
enhance HPV clearance (7, 8).  Analyses showed that the clearance rate of HPV16 
incident infections in the glans was lower in high viral load than low viral load infections 
at 6 months after HPV16 detection [aHR =0.58 (0.36-0.93)]. For both prevalent and 
incident infections, the risk of HPV16 persistence to 6 after detection was greater for 
high viral load than low viral load infections in the glans. A greater proportion of high 
viral load infections was observed in the glans than the shaft for both prevalent and 
incident HPV16 or HPV 18 infections. The risk of HPV16 or HPV18 persistence to 6 
months after detection was similar for high and low viral load infections in the shaft. 
To our knowledge this is the first study to examine the association between penile 
HPV viral load and HPV clearance. High HPV16 viral load in the glans was associated with 
a reduced HPV clearance, and thus, could possibly be associated with development of 
penile SCC. The lower clearance rate and longer duration of infection in men with high 
versus low HPV16 viral load could also explain the suggested increase in HPV16 
transmission to their female partners. 
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HPV viral load measurements in women have been suggested to have possible 
prognostic value in detecting HPV infections that are more likely to persist and possibly 
progress to CIN during HPV screening (45, 56). HPV screening in men is not 
recommended since penile HPV infections are common and likely to clear as shown in 
our results (64). These analyses add to the current understanding of the role of HPV 
viral load in penile HPV clearance and possibly penile SCC development in men, as 
well as transmission of HPV infections to their female partners. 
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